fluorouracil has been researched along with Peritoneal Neoplasms in 457 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 9.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "Fluorouracil, l-leucovorin and paclitaxel at Level 1 is feasible as first-line treatment for peritoneal disseminated gastric cancer patients with massive ascites or inadequate oral intake." | 9.16 | Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. ( Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H, 2012) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 9.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 9.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 9.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 9.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 9.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 7.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| " For therapeutic efficacy, the survival, tumor, and ascites inhibition of mice after treatment with (188)Re-liposomes and 5-fluorouracil (5-FU), respectively, were evaluated and compared." | 7.77 | Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. ( Chang, CH; Chang, TJ; Chang, YJ; Chen, LC; Ho, CL; Hsu, CW; Lan, KL; Lee, TW; Lee, WC; Liu, IH; Ni, HC; Ting, G; Tsai, CC; Wu, YH, 2011) |
| "To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma." | 7.74 | Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. ( Chen, CW; Hsieh, JS; Su, YC; Wang, JY; Wang, WM; Wu, JY, 2008) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "Pseudomyxoma peritonei, a tumor which spreads chiefly along peritoneal surfaces, has recently been treated by resection followed by intraperitoneal infusion of 5-fluorouracil (5-FU)." | 7.70 | Pseudomyxoma peritonei: Sudden cardiac death complicating post operative intraperitoneal treatment with 5-fluorouracil. ( El-Attar, AF; Howard, JM; Skeel, RT, 1999) |
| "A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks." | 7.69 | Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. ( Fujita, T; Hagiwara, A; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 7.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil." | 7.67 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. ( Blackshaw, AJ; Harvey, VJ; Ponder, BA; Slevin, ML; Wrigley, PF, 1984) |
| " Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66." | 6.90 | Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. ( Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019) |
| "The present study aimed to determine if oral methioninase (o-rMETase) combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with peritoneal-carcinomatosis formed from HCT-116 green fluorescent protein (GFP)-expressing colon-cancer cells implanted intra-peritoneally in nude mice." | 5.91 | Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis. ( Bouvet, M; Han, Q; Hoffman, RM; Kim, MJ; Park, JH, 2023) |
| "Peritoneal metastasis is common in gastric cancer." | 5.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 5.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 5.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma." | 5.24 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017) |
| "Fluorouracil, l-leucovorin and paclitaxel at Level 1 is feasible as first-line treatment for peritoneal disseminated gastric cancer patients with massive ascites or inadequate oral intake." | 5.16 | Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. ( Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H, 2012) |
| "A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule." | 5.14 | Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009) |
| "This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm." | 5.12 | Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. ( Benizri, E; Di Pietrantonio, D; Elias, D; Malka, D; Menegon, P; Raynard, B, 2007) |
| " In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i." | 5.11 | Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. ( Berglund, A; Glimelius, B; Graf, W; Hansson, J; Mahteme, H; Nygren, P; Påhlman, L, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 5.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 5.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 5.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.09 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M, 2000) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 5.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 5.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| " Loading of oxaliplatin (Ox) and 5-Fluorouracil (5-FU) into the thermogel were able to significantly decreased peritoneal carcinomatosis index (PCI) (-58%) and ascites (-70%) in a murine model of peritoneal metastases." | 4.02 | Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model. ( Al Sabbagh, C; Boudy, V; Mignet, N; Pimpie, C; Pocard, M; Roy, P; Seguin, J, 2021) |
| "We retrospectively evaluated the efficacy and safety of a chemotherapeutic regimen with 5-fluorouracil and oxaliplatin (modified FOLFOX6, mFOLFOX6) for patients with unresectable pseudomyxoma peritonei." | 3.96 | Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei. ( Hiraide, S; Imai, H; Ishioka, C; Komine, K; Ouchi, K; Saijo, K; Sato, Y; Shirota, H; Takahashi, M; Takahashi, S, 2020) |
| "This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice." | 3.96 | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020) |
| "Ten patients with histologically diagnosed peritoneal metastases of adenocarcinoma or pseudomyxoma peritonei underwent cytoreductive surgery and received HIPEC with 5-fluorouracil for 90 min, delivered via our modified system." | 3.83 | Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. ( Cavazos, M; Cravioto-Villanueva, A; Esquivel, J; Luna-Perez, P; Martinez-Gomez, H; Montiel, H; Ramirez, ML; Solorzano, J, 2016) |
| "A 71-year-old patient receiving combination chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil (5-FU)) for metastatic pancreas cancer was admitted after her first cycle of chemotherapy with a severe and unexpectedly prolonged episode of neutropenic sepsis associated with pancytopenia and marked mucositis." | 3.80 | A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. ( Gillmore, R; Suarez Martinez-Falero, B, 2014) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 3.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions." | 3.78 | First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. ( Hamaguchi, T; Iwasa, S; Kato, K; Nakajima, TE; Nakamura, K; Shimada, Y; Takashima, A; Yamada, Y, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| " For therapeutic efficacy, the survival, tumor, and ascites inhibition of mice after treatment with (188)Re-liposomes and 5-fluorouracil (5-FU), respectively, were evaluated and compared." | 3.77 | Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. ( Chang, CH; Chang, TJ; Chang, YJ; Chen, LC; Ho, CL; Hsu, CW; Lan, KL; Lee, TW; Lee, WC; Liu, IH; Ni, HC; Ting, G; Tsai, CC; Wu, YH, 2011) |
| "By modulating the route or timing of administration of 5-fluorouracil, it becomes a pharmacologic advantageous molecule in patients with peritoneal carcinomatosis of an appendiceal malignancy." | 3.76 | Pharmacology of perioperative 5-fluorouracil. ( Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2010) |
| "The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy." | 3.75 | Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009) |
| "As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU)." | 3.75 | Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. ( Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B, 2009) |
| "To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma." | 3.74 | Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. ( Chen, CW; Hsieh, JS; Su, YC; Wang, JY; Wang, WM; Wu, JY, 2008) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| " Retention of ascites, peritoneal dissemination, obstructive jaundice and right hydronephrosis appeared in June, 2003, and we started combination chemotherapy with paclitaxel and 5-fluorouracil." | 3.73 | [A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL]. ( Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S, 2005) |
| "Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively." | 3.73 | Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| "We present a case of a 28-year-old female with extensive, bulky malignant peritoneal epitheliod mesothelioma who underwent optimal cytoreduction with peritonectomy followed by intraoperative hyperthermic cisplatin and postoperative intraperitoneal paclitaxel and fluorouracil." | 3.73 | Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy. ( Bidus, MA; Elkas, JC; Kyser, K; Rodriguez, M; Rose, GS, 2006) |
| "A 64-year-old man on chronic hemodialysis for end-stage renal disease developed peritoneal carcinomatosis, and palliative chemotherapy with fluorouracil was started." | 3.73 | Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. ( Cartei, G; Ferrari, M; Ferrazzi, E; Gusella, M; Padrini, R; Rebeschini, M, 2005) |
| "A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen)." | 3.73 | Oxaliplatin-related acute myelogenous leukemia. ( Carneiro, BA; Eldibany, M; Kaminer, L; Kaul, K; Locker, GY; Sreekantaiah, C, 2006) |
| " In our report, a middle age patient suffering from locally advanced gastric cancer with peritonitis carcinomatosa and ascites was treated with neoadjuvant chemotherapy (DCF: docetaxel, cisplatin, fluorouracil protocol) successfully, as at the restaging examination total tumor regression was found." | 3.73 | [Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report]. ( Ember, A; Esik, O; Horváth, OP; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| " The mean values of 5-fluorouracil (5-FU) concentrations in ascites of the S-1 group at 1-4 h were 414-580 ng/ml (n=5), and those of FT group were 70-87 ng/ml (n=5), with significant differences between the two groups at each observation time." | 3.72 | Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. ( Hirakawa, K; Nakata, B; Yamagata, S, 2004) |
| "Direct intraperitoneal chemotherapy with cisplatin or mitomycin prevents peritoneal carcinomatosis in experimental investigations." | 3.71 | Prophylaxis of peritoneal carcinomatosis in experimental investigations. ( Boltze, C; Halangk, W; Hribaschek, A; Kuhn, R; Lippert, H; Pross, M; Ridwelski, K, 2001) |
| "Pseudomyxoma peritonei, a tumor which spreads chiefly along peritoneal surfaces, has recently been treated by resection followed by intraperitoneal infusion of 5-fluorouracil (5-FU)." | 3.70 | Pseudomyxoma peritonei: Sudden cardiac death complicating post operative intraperitoneal treatment with 5-fluorouracil. ( El-Attar, AF; Howard, JM; Skeel, RT, 1999) |
| " Adenocarcinoma patients receive mitomycin C and 5-fluorouracil; sarcoma patients receive cisplatin and doxorubicin." | 3.69 | Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. ( Sugarbaker, PH, 1994) |
| "The optimal schedule for the administration of 5-fluorouracil (5-FU) in the management of advanced colorectal cancer remains to be determined." | 3.69 | Bioavailability of subcutaneous 5-fluorouracil: a case report. ( Carlin, W; Dunlop, DJ; Eatock, MM; Soukop, M; Watson, DG, 1996) |
| "A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks." | 3.69 | Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. ( Fujita, T; Hagiwara, A; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 3.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Peritoneal cells were derived from a patient (PK) with adenocarcinoma of the colon during the course of cisplatin/5-fluorouracil (5-FUra) treatment." | 3.68 | Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. ( Haedicke, K; Kashani-Sabet, M; Leong, L; Lu, Y; Scanlon, KJ, 1990) |
| "Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil." | 3.67 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. ( Blackshaw, AJ; Harvey, VJ; Ponder, BA; Slevin, ML; Wrigley, PF, 1984) |
| " Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66." | 2.90 | Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. ( Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019) |
| "5-fluorouracil continuous infusion for gastric cancer with peritoneal metastasis." | 2.78 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). ( Boku, N; Denda, T; Doi, T; Fukuda, H; Goto, M; Hamamoto, Y; Nasu, J; Ohtsu, A; Shirao, K; Takashima, A; Yamada, Y; Yamaguchi, K, 2013) |
| "Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases." | 2.77 | The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. ( Bertrand, C; Ceelen, W; D'Hoore, A; Fieuws, S; Hompes, D; Kerger, J; Legendre, H; Peeters, M; Van Cutsem, E; Van der Speeten, K, 2012) |
| "Patients with advanced gastric cancer (AGC), clinically unresectable because of local invasion or limited intra-abdominal metastasis in para-aortic lymph nodes and/or the peritoneum based on multidetector row computed tomography, were enrolled." | 2.75 | Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH, 2010) |
| "Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5 year survival of 51%." | 2.75 | Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. ( Avital, I; Davis, JL; Kemp, CD; Ripley, RT; Steinberg, SM; Toomey, MA, 2010) |
| "This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers." | 2.74 | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Lee, KW; Lee, MH; Lee, NS; Oh, DY; Park, SR; Song, HS, 2009) |
| "The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy." | 2.73 | 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. ( Boot, H; Bruin, S; van Slooten, G; van Tinteren, H; Verwaal, VJ, 2008) |
| "Peritoneal carcinomatosis (PC), which has hitherto been regarded as a lethal entity, can now be cured with surgery (treating macroscopic tumor seeding) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) (treating residual microscopic disease)." | 2.73 | Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. ( Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B, 2007) |
| "An early detection and treatment of gastric cancer with peritoneal dissemination are rather difficult so that a clinical trial has been neglected." | 2.73 | [Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination]. ( Doki, Y; Fujiwara, Y; Miyata, H; Monden, M; Nishida, T; Takiguchi, S; Yamazaki, M, 2007) |
| "Capecitabine was administered beginning at 2000 mg/m2/day orally in two divided doses with meals on a 21-day cycle: 14 days of capecitabine followed by a 7-day rest period." | 2.72 | A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. ( Atkinson, N; Bodurka, DC; Branham, D; Gershenson, DM; Jenkins, AD; Sun, CC; Verschraegen, C; Wolf, JK, 2006) |
| "Colorectal peritoneal carcinomatosis (PC) is a frequent and very lethal event." | 2.71 | Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. ( Baton, O; Benhamou, E; Delperro, JR; Elias, D; Giovannini, M; Lasser, P; Pocard, M; Sideris, L, 2004) |
| "Peritoneal carcinomatosis in the absence of distant metastasis occurs in approximately 8 per cent of patients with colorectal cancer." | 2.71 | Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. ( van Ruth, S; van Tinteren, H; Verwaal, VJ; Zoetmulder, FA, 2004) |
| " Morbidity is a significant limitation of this procedure, usually related to the extent of surgery, and hematological toxicity, which is considered as dependent upon the chemotherapy dosage alone." | 2.71 | Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. ( Boige, V; Elias, D; Estphan, G; Laplanche, A; Malka, D; Pocard, M; Raynard, B, 2005) |
| "Patients with peritoneal carcinomatosis (PC) underwent complete cytoreductive surgery followed by intraoperative i." | 2.70 | Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. ( Antoun, S; Bonnay, M; Bourget, P; Ducreux, M; El Otmany, A; Elias, D; Lasser, P; Laurent, S; Paci, A, 2002) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| "Of 104 patients with peritoneal carcinomatosis from colon or rectal adenocarcinoma, five patients (4." | 2.69 | Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. ( Pestieau, SR; Sugarbaker, PH, 2000) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| "Recurrence of gastric cancer or colon cancer was observed in some patients who received 5-fluorouracil (5-FU) high-dose continuous Methotrexate (MTX)-Leucovorin (LV) therapy (FML therapy) previously." | 2.67 | [Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer]. ( Fujihara, T; Inokuchi, T; Kawano, K; Kimoto, K; Mori, F; Tamura, Y; Yoshioka, Y, 1994) |
| " The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1." | 2.67 | Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ( Hasegawa, M; Hasegawa, T; Ito, A; Kuzuya, T; Nabeshima, T; Yamauchi, M, 1994) |
| "Eighteen patients with gastric cancer with peritoneal metastasis were treated with methotrexate/5-fluorouracil sequential therapy." | 2.67 | [Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sejima, T; Sugaya, J; Takano, Y; Tomita, F, 1994) |
| "Metastatic colorectal cancer has evolved from a paradigm that was previously centered upon the use of systemic chemotherapy to one of multimodality therapy." | 2.47 | Surgical therapies in metastatic colorectal cancer with a potential for cure. ( Chua, TC; Esquivel, J; Koong, HN; Liauw, W, 2011) |
| "Because patients with advanced gastric cancers have less than 50% chance of cure after R0 resection, the need for an adjuvant treatment to eradicate residual microscopic disease is clear." | 2.43 | A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy. ( Yu, W, 2006) |
| "In addition, the PHREG analysis in 1453 gastric cancer patients showed that MF therapy (mitomycin C i." | 2.40 | Selection of adjuvant chemotherapy for gastric cancer using objective criteria. ( Nishiyama, M; Toge, T, 1997) |
| "The recurrence rate of resected gastric cancer with curative intent was around 20%." | 2.40 | [Treatment of recurrent gastric cancer]. ( Sakata, Y; Tsushima, K, 1998) |
| "A patient with recurrent breast cancer, who was diagnosed with eyelid metastasis as a part of systemic metastases and in whom systemic chemotherapy was markedly effective, is reported." | 2.39 | Eyelid metastasis from breast cancer showing marked response to chemotherapy. ( Abe, K; Adachi, I; Kaneko, A; Narabayashi, M; Tokue, Y; Tsuda, H; Watanabe, T; Yin, DF; Zhang, GJ, 1995) |
| "The present study aimed to determine if oral methioninase (o-rMETase) combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with peritoneal-carcinomatosis formed from HCT-116 green fluorescent protein (GFP)-expressing colon-cancer cells implanted intra-peritoneally in nude mice." | 1.91 | Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis. ( Bouvet, M; Han, Q; Hoffman, RM; Kim, MJ; Park, JH, 2023) |
| " This work aimed to investigate the clinical efficacy of intraperitoneal perfusion of fluorouracil and cisplatin combined with intravenous chemotherapy for the treatment of peritoneal metastasis in GC." | 1.91 | Clinical effectiveness of fluorouracil and cisplatin intraperitoneal perfusion combined with intravenous chemotherapy for peritoneal metastasis in gastric cancer. ( Chen, SY; Li, XQ; Mao, QC; Xiong, XH; Yang, JW, 2023) |
| " Common Terminology Criteria for Adverse Events v4." | 1.72 | Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. ( Alyami, M; Bakrin, N; Bardet, SM; Dumont, F; Durand Fontanier, S; Eveno, C; Gagniere, J; Glehen, O; Hübner, M; Pache, B; Pocard, M; Quenet, F; Sgarbura, O; Taibi, A; Teixeira Farinha, H; Thibaudeau, E, 2022) |
| "It revealed a peritoneal recurrence in the pouch of Douglas." | 1.72 | [A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection]. ( Arakawa, A; Ii, Y; Irie, T; Kawaguchi, M; Kawai, M; Kobari, A; Kojima, Y; Momose, H; Sakamoto, K; Sugimoto, K; Terao, Y; Tomiki, Y; Tsukamoto, R, 2022) |
| "Patients with PM from colorectal cancer and PCI >20 that were treated with CRS and HIPEC experience a one year longer and doubled overall survival compared with open-close/debulking patients." | 1.56 | Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Artursson, S; Birgisson, H; Cashin, P; Enblad, M; Ghanipour, L; Graf, W, 2020) |
| "By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC)." | 1.56 | Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. ( Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY, 2020) |
| "Adenocarcinoma ex-goblet cell carcinoids (AGCCs) are rare appendiceal tumors with mixed neuroendocrine and glandular features." | 1.51 | Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. ( Berlin, J; Das, S; Du, L; Idrees, K; Shi, C, 2019) |
| " No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups." | 1.51 | Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. ( Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis." | 1.51 | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. ( Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B, 2019) |
| "Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
| "Among 496 consecutive M1c colorectal cancer patients, R0 resection was achieved for 94 patients (19%)." | 1.48 | Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy. ( Kanemitsu, Y; Ochiai, H; Shida, D; Tsukamoto, S, 2018) |
| "A 67-year-old woman was diagnosed with cecal cancer, para-aortic lymph node metastasis, peritoneum dissemination, and left breast cancer." | 1.46 | [A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy]. ( Babaya, A; Hamanaka, M; Ikeda, M; Imada, A; Kimura, K; Kobayashi, M; Noda, M; Song, J; Tomita, N; Tsukamoto, K; Yamano, T, 2017) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy." | 1.46 | Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. ( Andrikou, K; Bianconi, M; Bittoni, A; Bracci, R; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Mandolesi, A; Scarpelli, M; Scartozzi, M, 2017) |
| "Peritoneal carcinomatosis (PC) from colorectal cancers (CRC) either at initial presentation or at subsequent recurrence presents a significant treatment challenge." | 1.46 | Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change. ( Bhamre, R; Bhandare, M; Engineer, R; Ostwal, V; Pai, V; Patil, P; Saklani, A, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 1.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| "Pseudomyxoma peritonei is a disease that results from a perforated mucinous neoplasm of the appendix so that mucinous ascites and mucin-producing tumor cells are widely disseminated in a characteristic pattern throughout the abdomen and pelvis." | 1.46 | Management of an inguinal hernia in patients with pseudomyxoma peritonei. ( Sugarbaker, PH, 2017) |
| "Metastatic liver disease from colorectal cancer is a significant clinical problem." | 1.43 | The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. ( Denys, A; Devun, F; Dutreix, M; Herath, NI; Herbette, A; Lienafa, MC; Sun, JS, 2016) |
| "The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox." | 1.43 | Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. ( Charrier, T; Cotte, E; Elias, D; Eveno, C; Glehen, O; Gocevska, S; Goere, D; Maurice, C; Ortega-Deballon, P; Passot, G; Peron, J; Pocard, M; Quénet, F; Vaudoyer, D, 2016) |
| "Pseudomyxoma peritonei is a very rare condition, and even rarer in patients with history of cancer." | 1.43 | Pseudomyxoma Peritonei in a Patient with History of Breast Cancer. ( Hong, JU; Jung, TS; Lee, HJ; Lee, JY; Min, IS; Park, SH; Seock, CH, 2016) |
| "The aim of this study is to discuss the curative effect of introperitoneal hyperthermic perfusion chemotherapy(IHPC) combined with systemic neoadjuvant chemotherapy on the gastric cancer patients with peritoneal carcinomatosis." | 1.43 | [Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis]. ( Chen, Y; Guo, Y; Suo, J; Wang, D; Xing, Y; Zhang, Y, 2016) |
| " This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value." | 1.43 | Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016) |
| "Even in cases of peritoneal recurrence of colon cancer, aggressive resection may improve the prognosis in some cases." | 1.42 | [Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report]. ( Hakamada, K; Miura, T; Nakayama, Y, 2015) |
| "Although hyperammonemia is known as one of the adverse side effects of 5-FU, a disturbance of consciousness caused by hyperammonemia is not a usual finding." | 1.42 | [A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer]. ( Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S, 2015) |
| "Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy." | 1.40 | Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. ( Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P, 2014) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| "Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the majority of whom present with unresectable disease." | 1.40 | A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. ( Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W, 2014) |
| "Long-term OS after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab." | 1.40 | Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. ( Ceelen, W; Pattyn, P; Putte, DV; Van Nieuwenhove, Y, 2014) |
| "They were divided into locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer (MPC)." | 1.40 | Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. ( Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY, 2014) |
| "We report a case of gastric cancer with peritoneal dissemination that was successfully treated with low-dose S-1 or capecitabine chemotherapy over a 5-year period." | 1.40 | [A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years]. ( Hara, Y; Minami, Y; Nakamura, T; Ueda, S, 2014) |
| "Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC)." | 1.40 | Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. ( Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S, 2014) |
| " Short-term efficacy and adverse reactions were observed." | 1.40 | [Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis]. ( Chen, T; Hu, Y; Li, G; Mou, T; Xia, W; Yu, J, 2014) |
| "A 77-year-old woman was diagnosed with gastric cancer complicated by multiple liver metastases and peritoneal dissemination." | 1.40 | [Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report]. ( Choda, Y; Harano, M; Idani, H; Kanazawa, T; Matsukawa, H; Ninomiya, M; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Tokumoto, N, 2014) |
| "There has been no disease recurrence 75 months after the initial surgery." | 1.40 | [Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report]. ( Kakizawa, N; Kato, T; Noda, H; Rikiyama, T; Toyama, N; Watanabe, F, 2014) |
| "A colonoscopy detected KRAS wild-type rectal cancer." | 1.40 | [A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)]. ( Aisu, Y; Ando, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T, 2014) |
| "Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare." | 1.40 | [A case of metastatic gastric cancer originating from transverse colon cancer]. ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014) |
| "All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy." | 1.40 | Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer. ( Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S, 2014) |
| " During HIPEC in Colliseum technique Oxaliplatin was given in a dosage of 200 mg/m2 and Docetaxel in a dosage of 80 mg/m2." | 1.40 | Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. . ( Hotopp, T; Müller, H; Tofeili, A; Wutke, K, 2014) |
| "Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival." | 1.39 | Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013) |
| "Colorectal carcinoma is rare in the paediatric population but is increasing in incidence." | 1.38 | Metastatic paediatric colorectal carcinoma. ( Kennedy, MJ; Larkin, JO; McCormick, P; Mehigan, B; Muldoon, C; Woods, R, 2012) |
| " FOLFOX4 combined with panitumumab therapy was initiated 1 month after the operation." | 1.38 | [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab]. ( Asano, T; Hattori, M; Kamiya, I; Negita, M; Takagi, D; Uemura, T, 2012) |
| "The majority of patients with gastric cancer in developing countries present with advanced disease." | 1.38 | Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. ( Guven, M; Inal, A; Işikdogan, A; Kaplan, MA; Kuçukoner, M; Nas, N; Urakci, Z; Yunce, M, 2012) |
| "A58 -year-old man with sigmoid colon cancer with peritoneal dissemination was treated with bevacizumab (BV) plus mFOLFOX6 therapy as third-line chemotherapy after treatment failures with FOLFOX4 and FOLFIRI regimen." | 1.36 | [A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI]. ( Fukuyama, T; Hachiya, Y; Hirano, Y; Hirata, K; Ishikawa, N; Koui, S; Minagawa, N; Nakashima, H; Sako, T; Tamura, T, 2010) |
| "However, G-CSF-producing colorectal cancer (CRC) has never been reported in the English literature." | 1.35 | Granulocyte-colony stimulating factor producing rectal cancer. ( Akamo, Y; Funahashi, H; Ochi, N; Sakamoto, M; Satoh, M; Sawai, H; Takahashi, H; Takayama, S; Takeyama, H; Wakasugi, T; Yasuda, A, 2008) |
| "In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported." | 1.35 | Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. ( Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| "We reported a case of super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy." | 1.35 | [Super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy--report of a case]. ( Fujita, S; Ishida, H; Kabuto, T; Nakaguchi, K; Wada, A; Watanabe, Y, 2008) |
| "A new animal model of esophageal cancer causing tumor colonization of the peritoneal cavity and producing bloody ascites was made by injecting YES-2 cells into the peritoneal cavity of a severe combined immunodeficiency mouse." | 1.35 | Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. ( Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T, 2009) |
| "Rapamycin suppressed advanced stage colorectal cancer, even with oral administration." | 1.35 | Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. ( Candinas, D; Egger, B; Hunt, KK; Laemmle, A; Roh, V; Strehlen, M; Stroka, D; Trochsler, M; Vorburger, SA; Wagner, M, 2009) |
| "A goblet cell carcinoid of the vermiform appendix was identified as the primary tumor." | 1.35 | [Metastazation into the seminal vesicles due to primary goblet cell carcinoid of the vermiform appendix. An unusual diagnostic procedure of a seminal vesicle tumor]. ( Flury, R; Gramann, T; Jaeger, P; Matter, L; Pfofe, D, 2009) |
| "Although peritoneal dissemination of gastric cancer is common and often causes deterioration of the patient's condition and quality of life (QOL), these patients are usually excluded from clinical trials." | 1.35 | Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. ( Boku, N; Fukutomi, A; Hironaka, S; Imazawa, M; Kojima, T; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H, 2009) |
| " The dose-response relationships for melphalan and irinotecan in individual samples showed great variability." | 1.35 | Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. ( Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A, 2008) |
| "The modern treatment of pseudomyxoma peritonei is cytoreductive surgery plus intraperitoneal chemotherapy resulting in a survival of up to 70 percent after 20 years." | 1.35 | Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. ( Hansen, F; Iversen, LH; Jess, P; Laurberg, S; Nielsen, MB; Rasmussen, PC, 2008) |
| "Patients with potentially resectable gastric cancer treated with preoperative CRT are found to be ineligible for surgery principally because of peritoneal progression." | 1.35 | Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. ( Ajani, JA; Badgwell, BD; Crane, CH; Das, P; Delclos, ME; Janjan, NA; Kim, MM; Krishnan, S; Mansfield, PF; Maru, D; Phan, AT, 2008) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 1.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| " From March 2002, we started to treat patients with advanced gastric cancer (stage IV) with a new regimen; intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells (intermittent FP ." | 1.34 | [The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S, 2007) |
| "A 55-year-old man with advanced gastric cancer underwent total gastrectomy (T3N0M0, stage II , por, sig) in the USA." | 1.34 | [A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel]. ( Akiyama, J; Hayashi, Y; Iwashita, R; Kobayakawa, M; Masaki, N; Nagaoki, Y; Nagata, N; Nozaki, Y; Oshima, T; Sako, A; Sakurai, T; Tamegai, Y; Uemura, N; Umeda, N; Watanabe, M; Yago, Y, 2007) |
| "The therapeutic efficacy of G207, a replication-competent herpes simplex virus, for malignancies is increased when combined with certain chemotherapies, but the mechanism is unclear and the interaction between G207 and surgical resection has not been extensively studied." | 1.33 | Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. ( Cohen, JB; Glorioso, JC; Kuroki, S; Nakano, K; Tanaka, M; Todo, T; Yamaguchi, K; Zhao, G, 2005) |
| " We conducted an analysis to evaluate the efficacy and feasibility of modified pharmacokinetic modulating chemotherapy, for gastric cancer patients with peritoneal dissemination." | 1.33 | [Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination]. ( Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005) |
| " As adverse effects of the following systemic chemotherapy, three patients had grade 3 anemia and one had grade 3 leukopenia." | 1.33 | [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination]. ( Bamba, T; Hanyu, T; Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Makino, S; Ohashi, M; Sakamoto, K; Tanabe, T; Yajima, K, 2005) |
| "The response of gastric cancer with peritoneal dissemination to systemic chemotherapy may be negatively affected by poor drug delivery due to the blood-peritoneal barrier." | 1.33 | Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. ( Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R, 2006) |
| "Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2." | 1.33 | Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006) |
| "Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy." | 1.33 | [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. ( Higuchi, K; Kobayashi, N; Koizumi, W; Mitomi, H; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2006) |
| "Human gastric cancer cells (MKN-45) were injected into the peritoneal cavity of nude mice." | 1.32 | Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. ( Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T, 2003) |
| "We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin." | 1.32 | [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. ( Aoki, T; Ichimiya, H; Kato, K; Katsumata, K; Okada, K; Wakana, Y, 2004) |
| "Mitomycin and cisplatin were highly effective to prevent peritoneal carcinomatosis (direct application immediately after tumor cell transfer - 1 (st) treatment group)." | 1.32 | [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis]. ( Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K, 2004) |
| "The VIPoma syndrome is rare." | 1.31 | Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. ( Barbier, JP; Berger, A; Carnot, F; Cellier, C; Cuillerier, E; Haddad, C; Landi, B; Siauve, N; Yaghi, C, 2000) |
| "Lymph node metastasis was not present." | 1.31 | [Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report]. ( Iesato, H; Morishita, Y; Nakagami, K; Ohwada, S; Ohya, T; Sasaki, T; Sugitani, K; Takahashi, T; Yokomori, T, 2000) |
| "We encountered a case of unresectable colon cancer that disappeared following pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)]. ( Asahara, T; Nakahara, H; Nakahara, M; Okajima, M; Yano, M, 2000) |
| "5-Fluorouracil and cisplatin were administered intraperitoneally on postoperative days 1-4, and this was repeated at 4-week intervals." | 1.31 | Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. ( Chung, HC; Min, JS; Noh, SH; Roh, JK; Shin, DW; Yoo, CH, 2001) |
| "Diffuse pyogenic gelatinous ascites and a large cystic mass with a grayish wall, and a hard solid lesion in part were found." | 1.31 | Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case. ( Kuroki, Y; Otagiri, S; Tsukada, K, 2001) |
| "The outcome of patients with mucinous appendiceal neoplasms with peritoneal surface dissemination has changed as a result of a better understanding of the clinical and pathologic features of this disease." | 1.31 | Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. ( Esquivel, J; Sugarbaker, PH, 2001) |
| "Most gastric cancer patients with peritoneal dissemination have been excluded from clinical studies because they usually have no measurable lesions." | 1.31 | Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. ( Boku, N; Hironaka, S; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Tahara, M; Tajiri, H; Yoshida, M; Yoshida, S, 2001) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| "Fluorouracil was given p." | 1.30 | [Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer]. ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Murata, K; Nakano, H; Ohigashi, H; Sasaki, Y; Yasuda, T, 1998) |
| "The patient was diagnosed to have gastric cancer (T3 N3 M0 P3, Stage IV b)." | 1.30 | [Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival]. ( Horimi, T; Morita, S; Takahashi, I; Takamatsu, M; Takasaki, M; Tsuji, A, 1998) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy." | 1.29 | [Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy]. ( Ikeda, K; Shibata, N; Tamai, M, 1995) |
| "Three cases of postoperative gastric cancer with peritoneal dissemination were treated by combined administration of CDDP, 5-FU and Lentinan." | 1.29 | [Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan]. ( Mio, H; Terabe, K, 1994) |
| " Cavitation was produced by various SW regimens (250 to 750SW) combined with bubbles (air/gelatin emulsion) infused through an IP catheter." | 1.29 | In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat. ( Cathignol, D; Chapelon, JY; el Fadil, FA; Ponchon, T; Prat, F; Theillère, Y, 1993) |
| "There were 43 colorectal and 104 appendiceal cancer patients." | 1.29 | Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996) |
| "Peritoneal carcinomatosis has been regarded as a uniformly lethal clinical entity with no specific plan for management." | 1.29 | Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. ( Sugarbaker, PH, 1996) |
| "Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix." | 1.29 | Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996) |
| " A marked pharmacokinetic advantage was observed when 5-FU and CDDP were administered." | 1.28 | [Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer]. ( Ito, A; Ito, K; Kodera, Y; Kondo, K; Kuzuya, T; Nagai, S; Nakahara, H; Satta, T; Takagi, H; Yamauchi, M, 1992) |
| "5-Fluorouracil was given on postoperative days 2-5 at 15 and 20 mg/kg, respectively." | 1.28 | Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. ( Cunliffe, WJ; DeBruijn, EA; Graves, T; Hull, WE; Mullins, RE; Oliff, L; Schlag, P; Sugarbaker, PH, 1990) |
| " 5-FU was administered intracavitary in all patients combined with systemic chemotherapy." | 1.28 | Intracavitary 5-fluoro-uracil (5-FU) in combination with systemic chemotherapy. ( Boaziz, C; Breau, JL; Delanian, S; Israel, L; Morere, JF, 1989) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (7.00) | 18.7374 |
| 1990's | 73 (15.97) | 18.2507 |
| 2000's | 158 (34.57) | 29.6817 |
| 2010's | 163 (35.67) | 24.3611 |
| 2020's | 31 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, H | 2 |
| Inoue, E | 1 |
| Yamaguchi, K | 7 |
| Boku, N | 8 |
| Hara, H | 2 |
| Nishina, T | 4 |
| Tsuda, M | 1 |
| Shitara, K | 5 |
| Shinozaki, K | 2 |
| Nakamura, S | 2 |
| Hyodo, I | 3 |
| Muro, K | 8 |
| Sasako, M | 1 |
| Terashima, M | 7 |
| Nakajima, TE | 6 |
| Taibi, A | 3 |
| Sgarbura, O | 1 |
| Hübner, M | 1 |
| Bardet, SM | 1 |
| Alyami, M | 1 |
| Bakrin, N | 1 |
| Durand Fontanier, S | 1 |
| Eveno, C | 6 |
| Gagniere, J | 1 |
| Pache, B | 1 |
| Pocard, M | 15 |
| Quenet, F | 4 |
| Teixeira Farinha, H | 1 |
| Thibaudeau, E | 1 |
| Dumont, F | 3 |
| Glehen, O | 7 |
| Sugarbaker, PH | 37 |
| Ii, Y | 1 |
| Irie, T | 2 |
| Kobari, A | 1 |
| Kawaguchi, M | 1 |
| Momose, H | 1 |
| Tsukamoto, R | 1 |
| Kawai, M | 2 |
| Sugimoto, K | 3 |
| Kojima, Y | 1 |
| Arakawa, A | 1 |
| Terao, Y | 1 |
| Tomiki, Y | 1 |
| Sakamoto, K | 2 |
| Mariani, A | 3 |
| Zaanan, A | 4 |
| Karoui, M | 3 |
| Chia, DKA | 1 |
| Sundar, R | 1 |
| Kim, G | 1 |
| Ang, JJ | 1 |
| Shabbir, A | 2 |
| So, JBY | 1 |
| Yong, WP | 2 |
| Kim, MJ | 2 |
| Han, Q | 1 |
| Bouvet, M | 1 |
| Hoffman, RM | 1 |
| Park, JH | 1 |
| Xiong, XH | 1 |
| Mao, QC | 1 |
| Yang, JW | 1 |
| Chen, SY | 1 |
| Li, XQ | 1 |
| Lo Dico, R | 4 |
| Kaci, R | 3 |
| Naneix, AL | 2 |
| Malgras, B | 1 |
| Mathonnet, M | 2 |
| Bonnet, E | 1 |
| Mastier, C | 1 |
| Lardy-Cléaud, A | 1 |
| Rochefort, P | 1 |
| Sarabi, M | 1 |
| Guibert, P | 1 |
| Cattey-Javouhey, A | 1 |
| Desseigne, F | 1 |
| de La Fouchardière, C | 1 |
| Lin, YL | 1 |
| Zhang, J | 1 |
| Yan, FC | 1 |
| Jiang, X | 1 |
| Ma, R | 1 |
| Yang, ZR | 1 |
| Xu, HB | 1 |
| Peng, Z | 1 |
| Chen, Q | 1 |
| Li, Y | 5 |
| de Boer, NL | 2 |
| Brandt-Kerkhof, ARM | 3 |
| Madsen, EVE | 3 |
| Diepeveen, M | 1 |
| van Meerten, E | 3 |
| van Eerden, RAG | 1 |
| de Man, FM | 1 |
| Bouamar, R | 1 |
| Koolen, SLW | 1 |
| de Hingh, IHJT | 4 |
| Bakkers, C | 4 |
| Rovers, KP | 4 |
| Creemers, GM | 4 |
| Deenen, MJ | 1 |
| Kranenburg, OW | 1 |
| Constantinides, A | 1 |
| Mathijssen, RHJ | 1 |
| Verhoef, C | 2 |
| Burger, JWA | 4 |
| Hiraide, S | 1 |
| Komine, K | 1 |
| Sato, Y | 2 |
| Ouchi, K | 1 |
| Imai, H | 1 |
| Saijo, K | 1 |
| Takahashi, M | 5 |
| Takahashi, S | 3 |
| Shirota, H | 1 |
| Ishioka, C | 1 |
| Archid, R | 1 |
| Zieker, D | 1 |
| Weinreich, FJ | 1 |
| Hönes, F | 1 |
| Königsrainer, A | 2 |
| Quintanilla-Martínez, L | 1 |
| Reymond, MA | 1 |
| Solass, W | 1 |
| Mizusawa, J | 2 |
| Sakamoto, T | 1 |
| Katayama, H | 1 |
| Takatsuno, Y | 1 |
| Kondo, I | 1 |
| Hayashi, K | 2 |
| Hasegawa, K | 1 |
| Maejima, K | 1 |
| Kaneko, J | 1 |
| Maejima, S | 1 |
| Yamano, T | 2 |
| Kubo, S | 1 |
| Tomita, N | 2 |
| Kitagawa, Y | 1 |
| Osumi, H | 1 |
| Shinozaki, E | 1 |
| Ota, Y | 1 |
| Nakayama, I | 1 |
| Suzuki, T | 2 |
| Wakatsuki, T | 1 |
| Ogura, M | 1 |
| Ooki, A | 1 |
| Takahari, D | 5 |
| Suenaga, M | 1 |
| Chin, K | 1 |
| Bockorny, B | 1 |
| Semenisty, V | 1 |
| Macarulla, T | 1 |
| Borazanci, E | 1 |
| Wolpin, BM | 1 |
| Stemmer, SM | 1 |
| Golan, T | 1 |
| Geva, R | 1 |
| Borad, MJ | 1 |
| Pedersen, KS | 1 |
| Park, JO | 2 |
| Ramirez, RA | 1 |
| Abad, DG | 1 |
| Feliu, J | 2 |
| Muñoz, A | 1 |
| Ponz-Sarvise, M | 1 |
| Peled, A | 1 |
| Lustig, TM | 1 |
| Bohana-Kashtan, O | 1 |
| Shaw, SM | 1 |
| Sorani, E | 1 |
| Chaney, M | 1 |
| Kadosh, S | 1 |
| Vainstein Haras, A | 1 |
| Von Hoff, DD | 1 |
| Hidalgo, M | 1 |
| Hanaka, J | 1 |
| Goya, T | 1 |
| van Erning, FN | 1 |
| Nienhuijs, SW | 3 |
| Simkens, GAAM | 2 |
| Hemmer, PHJ | 3 |
| Punt, CJA | 3 |
| Lemmens, VEPP | 1 |
| Tanis, PJ | 3 |
| Birgisson, H | 1 |
| Enblad, M | 1 |
| Artursson, S | 1 |
| Ghanipour, L | 1 |
| Cashin, P | 1 |
| Graf, W | 8 |
| Lee, JC | 1 |
| Woo, SM | 1 |
| Shin, DW | 2 |
| Kim, J | 2 |
| Yang, SY | 1 |
| Kim, JW | 2 |
| Lee, WJ | 1 |
| Cha, HS | 1 |
| Park, P | 1 |
| Hwang, JH | 1 |
| Nagourney, RA | 1 |
| Evans, S | 1 |
| Tran, PH | 1 |
| Nagourney, AJ | 1 |
| Patel, S | 1 |
| Pandey, D | 1 |
| Saklani, A | 2 |
| King, BH | 1 |
| Baumgartner, JM | 1 |
| Kelly, KJ | 1 |
| Marmor, RA | 1 |
| Lowy, AM | 1 |
| Veerapong, J | 1 |
| Luo, M | 1 |
| Barrak, D | 1 |
| Desale, S | 1 |
| Yoon, JJ | 1 |
| Dugan, MM | 1 |
| Kodavanti, PP | 1 |
| Sampah, ME | 1 |
| Mulens-Arias, V | 1 |
| Nicolás-Boluda, A | 1 |
| Pinto, A | 1 |
| Balfourier, A | 1 |
| Carn, F | 1 |
| Silva, AKA | 1 |
| Gazeau, F | 1 |
| Nindra, U | 1 |
| Shahnam, A | 1 |
| Mahon, KL | 1 |
| Seguin, J | 1 |
| Pimpie, C | 2 |
| Roy, P | 1 |
| Al Sabbagh, C | 1 |
| Mignet, N | 1 |
| Boudy, V | 1 |
| Thijs, AMJ | 2 |
| Tuynman, JB | 2 |
| Kusters, M | 2 |
| Versteeg, KS | 1 |
| Aalbers, AGJ | 2 |
| Kok, NFM | 2 |
| Buffart, TE | 1 |
| Wiezer, MJ | 2 |
| Boerma, D | 2 |
| Los, M | 2 |
| de Reuver, PR | 2 |
| Bremers, AJA | 2 |
| Verheul, HMW | 2 |
| Kruijff, S | 2 |
| de Groot, DJA | 2 |
| Witkamp, AJ | 4 |
| van Grevenstein, WMU | 2 |
| Koopman, M | 3 |
| Nederend, J | 2 |
| Lahaye, MJ | 2 |
| Kranenburg, O | 2 |
| Fijneman, RJA | 2 |
| van 't Erve, I | 2 |
| Snaebjornsson, P | 2 |
| Dijkgraaf, MGW | 2 |
| Al-Batran, SE | 2 |
| Homann, N | 1 |
| Pauligk, C | 1 |
| Illerhaus, G | 1 |
| Martens, UM | 1 |
| Stoehlmacher, J | 1 |
| Schmalenberg, H | 1 |
| Luley, KB | 1 |
| Prasnikar, N | 1 |
| Egger, M | 1 |
| Probst, S | 1 |
| Messmann, H | 1 |
| Moehler, M | 2 |
| Fischbach, W | 1 |
| Hartmann, JT | 2 |
| Mayer, F | 1 |
| Höffkes, HG | 1 |
| Koenigsmann, M | 1 |
| Arnold, D | 2 |
| Kraus, TW | 1 |
| Grimm, K | 1 |
| Berkhoff, S | 1 |
| Post, S | 1 |
| Jäger, E | 1 |
| Bechstein, W | 1 |
| Ronellenfitsch, U | 1 |
| Mönig, S | 1 |
| Hofheinz, RD | 1 |
| Lieto, E | 1 |
| Auricchio, A | 1 |
| Cardella, F | 1 |
| Mabilia, A | 1 |
| Basile, N | 1 |
| Castellano, P | 1 |
| Orditura, M | 1 |
| Galizia, G | 1 |
| Liaw, CC | 1 |
| Chuang, CK | 1 |
| Chang, YH | 1 |
| Liao, TY | 1 |
| Chang, JW | 1 |
| Juan, YH | 1 |
| Shida, D | 3 |
| Tsukamoto, S | 2 |
| Ochiai, H | 2 |
| Kanemitsu, Y | 2 |
| Masuishi, T | 2 |
| Kadowaki, S | 1 |
| Kondo, M | 1 |
| Komori, A | 1 |
| Sugiyama, K | 2 |
| Mitani, S | 1 |
| Honda, K | 2 |
| Narita, Y | 1 |
| Taniguchi, H | 2 |
| Ura, T | 3 |
| Ando, M | 1 |
| Mishima, H | 2 |
| Kimura, K | 2 |
| Noda, M | 1 |
| Imada, A | 1 |
| Song, J | 1 |
| Babaya, A | 1 |
| Hamanaka, M | 1 |
| Kobayashi, M | 2 |
| Tsukamoto, K | 1 |
| Ikeda, M | 2 |
| Cashin, PH | 2 |
| Mahteme, H | 9 |
| Syk, I | 2 |
| Frödin, JE | 2 |
| Glimelius, B | 4 |
| Mayanagi, S | 1 |
| Kashiwabara, K | 1 |
| Honda, M | 1 |
| Oba, K | 1 |
| Aoyama, T | 1 |
| Kanda, M | 2 |
| Maeda, H | 1 |
| Hamada, C | 2 |
| Sadahiro, S | 1 |
| Sakamoto, J | 2 |
| Saji, S | 1 |
| Yoshikawa, T | 2 |
| Yoshida, T | 6 |
| Tanabe, T | 2 |
| Das, S | 1 |
| Shi, C | 1 |
| Du, L | 1 |
| Idrees, K | 1 |
| Berlin, J | 1 |
| Knödler, M | 1 |
| Körfer, J | 1 |
| Kunzmann, V | 2 |
| Trojan, J | 1 |
| Daum, S | 1 |
| Schenk, M | 1 |
| Kullmann, F | 1 |
| Schroll, S | 1 |
| Behringer, D | 1 |
| Stahl, M | 1 |
| Hacker, U | 1 |
| Ibach, S | 1 |
| Lindhofer, H | 1 |
| Lordick, F | 2 |
| Murono, K | 1 |
| Nagata, H | 1 |
| Ishimaru, K | 1 |
| Emoto, S | 1 |
| Kaneko, M | 1 |
| Hiyoshi, M | 1 |
| Sasaki, K | 1 |
| Otani, K | 1 |
| Shuno, Y | 1 |
| Nishikawa, T | 1 |
| Tanaka, T | 3 |
| Hata, K | 1 |
| Kawai, K | 1 |
| Nozawa, H | 1 |
| Ishihara, S | 1 |
| Lin, HY | 1 |
| Kuo, WT | 1 |
| Hsu, CW | 2 |
| Fanotto, V | 1 |
| Fornaro, L | 1 |
| Bordonaro, R | 1 |
| Rosati, G | 2 |
| Rimassa, L | 1 |
| Di Donato, S | 1 |
| Santini, D | 1 |
| Tomasello, G | 1 |
| Leone, F | 1 |
| Silvestris, N | 1 |
| Stragliotto, S | 1 |
| Scartozzi, M | 2 |
| Giampieri, R | 2 |
| Nichetti, F | 1 |
| Antonuzzo, L | 1 |
| Cinieri, S | 1 |
| Avallone, A | 1 |
| Pellegrino, A | 1 |
| Melisi, D | 1 |
| Vasile, E | 1 |
| Gerratana, L | 1 |
| Aprile, G | 1 |
| Roviello, G | 1 |
| Petrioli, R | 1 |
| Rosellini, P | 1 |
| Multari, AG | 1 |
| Conca, R | 1 |
| Paganini, G | 1 |
| Chiriacò, G | 1 |
| Aieta, M | 1 |
| Sun, Y | 1 |
| Wu, X | 1 |
| Zhang, Y | 2 |
| Lin, H | 1 |
| Lu, X | 1 |
| Huang, Y | 1 |
| Chi, P | 1 |
| Ayez, N | 1 |
| Sluiter, NR | 1 |
| van der Vliet, HJ | 1 |
| Wassenaar, ECE | 1 |
| Hunting, CB | 1 |
| Kuhlmann, KFD | 1 |
| Boot, H | 6 |
| Chalabi, M | 1 |
| Been, LB | 1 |
| van Ginkel, RJ | 1 |
| Fehrmann, RSN | 1 |
| de Wilt, JHW | 1 |
| Radema, SA | 1 |
| Herbschleb, KH | 1 |
| Haj Mohammad, N | 1 |
| van Duyn, EB | 1 |
| Mastboom, WJB | 1 |
| Mekenkamp, LJM | 1 |
| van Laarhoven, HWM | 1 |
| Zwinderman, AH | 1 |
| Bouma, JM | 1 |
| Burnett, A | 1 |
| Lecompte, MA | 1 |
| Trabulsi, N | 1 |
| Dubé, P | 3 |
| Gervais, MK | 1 |
| Trilling, B | 1 |
| Cloutier, AS | 1 |
| Sideris, L | 6 |
| Pintova, S | 1 |
| Dharmupari, S | 1 |
| Moshier, E | 1 |
| Zubizarreta, N | 1 |
| Ang, C | 1 |
| Holcombe, RF | 1 |
| Iwasa, S | 4 |
| Kawahira, M | 1 |
| Yasui, H | 6 |
| Minashi, K | 1 |
| Hironaka, S | 5 |
| Fukuda, N | 1 |
| Horvath, P | 1 |
| Beckert, S | 1 |
| Nadalin, S | 1 |
| Königsrainer, I | 1 |
| Turner, KM | 1 |
| Hanna, NN | 1 |
| Zhu, Y | 2 |
| Jain, A | 1 |
| Kesmodel, SB | 1 |
| Switzer, RA | 1 |
| Taylor, LM | 1 |
| Richard Alexander, H | 1 |
| Kerscher, AG | 2 |
| Chua, TC | 8 |
| Gasser, M | 1 |
| Maeder, U | 2 |
| Isbert, C | 1 |
| Germer, CT | 2 |
| Pelz, JO | 2 |
| Quinn, LE | 1 |
| Zhao, J | 2 |
| Morris, DL | 10 |
| Trusilova, EV | 1 |
| Besova, NS | 1 |
| Bagrova, SG | 1 |
| Gorbunova, VA | 1 |
| Stilidi, IS | 1 |
| Nered, SN | 1 |
| Tezuka, T | 1 |
| Ishida, H | 4 |
| Ooshiro, M | 1 |
| Matsuoka, H | 1 |
| Kawasaki, S | 1 |
| Maeda, K | 1 |
| Koda, K | 1 |
| Katayama, K | 1 |
| Nishino, T | 1 |
| Takahashi, Y | 1 |
| Okitsu, H | 1 |
| Okitsu, N | 1 |
| Hamano, G | 1 |
| Ikebe, T | 1 |
| Mayumi, K | 2 |
| Takemura, M | 1 |
| Hori, T | 1 |
| Nishioka, T | 1 |
| Shirao, K | 3 |
| Yamada, Y | 4 |
| Doi, T | 1 |
| Goto, M | 2 |
| Nasu, J | 1 |
| Denda, T | 1 |
| Hamamoto, Y | 2 |
| Takashima, A | 3 |
| Fukuda, H | 1 |
| Ohtsu, A | 4 |
| Watanabe, K | 3 |
| Kawahara, H | 3 |
| Enomoto, H | 2 |
| Toyama, Y | 1 |
| Akiba, T | 2 |
| Yanaga, K | 2 |
| Kubo, H | 2 |
| Nakasuga, C | 1 |
| Tada, K | 2 |
| Miyahara, M | 2 |
| Hasegawa, H | 1 |
| Stiekema, J | 1 |
| Trip, AK | 1 |
| Jansen, EP | 1 |
| Cats, A | 1 |
| Ponz, OB | 1 |
| Verheij, M | 1 |
| van Sandick, JW | 1 |
| Passot, G | 2 |
| Goéré, D | 9 |
| Soyer, P | 1 |
| Gayat, E | 2 |
| Elias, D | 18 |
| Pillai, K | 1 |
| Ehteda, A | 1 |
| Akhter, J | 1 |
| Shimizu, T | 2 |
| Sonoda, H | 1 |
| Murata, S | 1 |
| Takebayashi, K | 1 |
| Ohta, H | 2 |
| Miyake, T | 1 |
| Mekata, E | 1 |
| Shiomi, H | 1 |
| Naka, S | 1 |
| Tani, T | 1 |
| Tomoda, M | 1 |
| Hompes, D | 2 |
| Aalbers, A | 1 |
| van Velthuysen, ML | 1 |
| Vogel, W | 1 |
| Prevoo, W | 1 |
| van Tinteren, H | 4 |
| Verwaal, V | 1 |
| Suarez Martinez-Falero, B | 1 |
| Gillmore, R | 1 |
| Miyamoto, M | 1 |
| Kirii, Y | 1 |
| Takagi, H | 3 |
| Ceelen, W | 2 |
| Van Nieuwenhove, Y | 1 |
| Putte, DV | 1 |
| Pattyn, P | 1 |
| Rau, B | 1 |
| Tang, Q | 1 |
| Wang, Y | 3 |
| Huang, R | 1 |
| You, Q | 1 |
| Wang, G | 1 |
| Chen, Y | 4 |
| Jiang, Z | 1 |
| Liu, Z | 1 |
| Yu, L | 1 |
| Muhammad, S | 1 |
| Wang, X | 1 |
| Pietrantonio, F | 1 |
| Maggi, C | 1 |
| Fanetti, G | 1 |
| Iacovelli, R | 1 |
| Di Bartolomeo, M | 1 |
| Ricchini, F | 1 |
| Deraco, M | 1 |
| Perrone, F | 1 |
| Baratti, D | 1 |
| Kusamura, S | 1 |
| Tamborini, E | 1 |
| Castano, A | 1 |
| Consonni, PV | 1 |
| Bossi, I | 1 |
| Gavazzi, C | 1 |
| Milione, M | 1 |
| Pelosi, G | 1 |
| de Braud, F | 1 |
| Jo, JH | 1 |
| Chung, MJ | 1 |
| Park, JY | 1 |
| Bang, S | 1 |
| Park, SW | 1 |
| Chung, JB | 1 |
| Song, SY | 1 |
| Rudloff, U | 2 |
| Langan, RC | 1 |
| Mullinax, JE | 1 |
| Beane, JD | 1 |
| Steinberg, SM | 3 |
| Beresnev, T | 2 |
| Webb, CC | 1 |
| Walker, M | 1 |
| Toomey, MA | 2 |
| Schrump, D | 1 |
| Pandalai, P | 2 |
| Stojadinovic, A | 3 |
| Avital, I | 3 |
| Ueda, S | 1 |
| Minami, Y | 1 |
| Hara, Y | 2 |
| Nakamura, T | 1 |
| Schaeffer, DF | 1 |
| Yoshida, EM | 1 |
| Koido, S | 1 |
| Kan, S | 1 |
| Yoshida, K | 2 |
| Yoshizaki, S | 1 |
| Takakura, K | 1 |
| Namiki, Y | 1 |
| Tsukinaga, S | 1 |
| Odahara, S | 1 |
| Kajihara, M | 1 |
| Okamoto, M | 1 |
| Ito, M | 1 |
| Yusa, S | 1 |
| Gong, J | 1 |
| Sugiyama, H | 1 |
| Ohkusa, T | 1 |
| Homma, S | 1 |
| Tajiri, H | 2 |
| Xia, W | 1 |
| Hu, Y | 1 |
| Mou, T | 1 |
| Chen, T | 1 |
| Yu, J | 1 |
| Li, G | 1 |
| Choda, Y | 1 |
| Ninomiya, M | 4 |
| Kanazawa, T | 1 |
| Sato, D | 1 |
| Tokumoto, N | 1 |
| Harano, M | 1 |
| Matsukawa, H | 1 |
| Ojima, Y | 1 |
| Idani, H | 1 |
| Shiozaki, S | 1 |
| Okajima, M | 2 |
| Choe, JH | 1 |
| Overman, MJ | 1 |
| Fournier, KF | 1 |
| Royal, RE | 2 |
| Ohinata, A | 1 |
| Rafeeq, S | 1 |
| Beaty, K | 1 |
| Phillips, JK | 1 |
| Wolff, RA | 1 |
| Mansfield, PF | 2 |
| Eng, C | 1 |
| Kato, T | 4 |
| Noda, H | 1 |
| Watanabe, F | 1 |
| Kakizawa, N | 1 |
| Toyama, N | 1 |
| Rikiyama, T | 1 |
| Milovanov, V | 1 |
| Sardi, A | 1 |
| Ledakis, P | 1 |
| Aydin, N | 1 |
| Nieroda, C | 1 |
| Sittig, M | 1 |
| Nunez, M | 1 |
| Gushchin, V | 2 |
| Yonemitsu, K | 1 |
| Kawamoto, S | 1 |
| Maeno, H | 1 |
| Okubo, S | 1 |
| Hosaka, S | 1 |
| Umemoto, S | 1 |
| Ohara, C | 1 |
| Ando, Y | 1 |
| Kadokawa, Y | 1 |
| Aisu, Y | 1 |
| Nishino, H | 1 |
| Nishiuchi, A | 1 |
| Kato, S | 1 |
| Machimoto, T | 1 |
| Asao, Y | 1 |
| Furuyama, H | 1 |
| Yoshimura, T | 1 |
| Nushijima, Y | 1 |
| Nakano, K | 2 |
| Nakaguchi, K | 2 |
| Kan, K | 1 |
| Maruyama, H | 1 |
| Doi, S | 1 |
| Okamura, S | 1 |
| Murata, K | 2 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Cayir, K | 1 |
| Simsek, M | 1 |
| Bilici, M | 1 |
| Tekin, SB | 1 |
| Yildirim, N | 1 |
| Bilen, N | 1 |
| Makas, I | 1 |
| Lam, JY | 1 |
| McConnell, YJ | 2 |
| Rivard, JD | 1 |
| Temple, WJ | 2 |
| Mack, LA | 2 |
| Ho, MY | 1 |
| Kennecke, HF | 1 |
| Renouf, DJ | 1 |
| Cheung, WY | 1 |
| Lim, HJ | 1 |
| Gill, S | 2 |
| Tsutsumi, S | 1 |
| Fujii, T | 2 |
| Yamaguchi, S | 1 |
| Suto, T | 1 |
| Yajima, R | 1 |
| Morita, H | 1 |
| Asao, T | 1 |
| Kuwano, H | 1 |
| Müller, H | 1 |
| Hotopp, T | 1 |
| Tofeili, A | 1 |
| Wutke, K | 1 |
| Bibeau, F | 1 |
| Gurung, S | 1 |
| Fu, H | 1 |
| Zhang, WW | 1 |
| Gu, YH | 1 |
| Bjersand, K | 1 |
| Sundström Poromaa, I | 1 |
| Andréasson, H | 1 |
| Larsson, R | 2 |
| Nygren, P | 3 |
| Dartigues, P | 2 |
| Stamou, K | 1 |
| Tsamis, D | 1 |
| Pallas, N | 1 |
| Samanta, E | 1 |
| Courcoutsakis, N | 1 |
| Prassopoulos, P | 1 |
| Tentes, AA | 1 |
| Gotoh, M | 2 |
| Shimada, Y | 6 |
| Kawai, H | 2 |
| Nakayama, N | 3 |
| Amagai, K | 1 |
| Nakamura, K | 3 |
| Herath, NI | 1 |
| Devun, F | 1 |
| Lienafa, MC | 1 |
| Herbette, A | 1 |
| Denys, A | 1 |
| Sun, JS | 1 |
| Dutreix, M | 1 |
| Spång, N | 1 |
| Torkzad, M | 1 |
| Maccaroni, E | 1 |
| Mandolesi, A | 1 |
| Del Prete, M | 1 |
| Andrikou, K | 1 |
| Faloppi, L | 1 |
| Bittoni, A | 1 |
| Bianconi, M | 1 |
| Scarpelli, M | 1 |
| Bracci, R | 1 |
| Cascinu, S | 1 |
| Nakayama, Y | 1 |
| Miura, T | 1 |
| Hakamada, K | 1 |
| Kagawa, Y | 1 |
| Naito, A | 1 |
| Murakami, K | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Okishiro, M | 1 |
| Takeno, A | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Tamura, S | 3 |
| Tan, GH | 1 |
| Ong, WS | 1 |
| Chia, CS | 1 |
| Tham, CK | 1 |
| Soo, KC | 1 |
| Teo, MC | 1 |
| Tebbutt, NC | 1 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 1 |
| Gebski, V | 1 |
| Charrier, T | 1 |
| Peron, J | 1 |
| Maurice, C | 1 |
| Gocevska, S | 1 |
| Ortega-Deballon, P | 1 |
| Vaudoyer, D | 1 |
| Cotte, E | 1 |
| Jung, TS | 1 |
| Hong, JU | 1 |
| Park, SH | 2 |
| Lee, HJ | 1 |
| Min, IS | 1 |
| Lee, JY | 1 |
| Seock, CH | 1 |
| Kishi, K | 2 |
| Fujiwara, Y | 5 |
| Yano, M | 5 |
| Motoori, M | 1 |
| Sugimura, K | 2 |
| Takahashi, H | 2 |
| Ohue, M | 1 |
| Sakon, M | 1 |
| Stein, SM | 1 |
| James, ES | 1 |
| Deng, Y | 1 |
| Cong, X | 1 |
| Kortmansky, JS | 1 |
| Li, J | 1 |
| Staugaard, C | 1 |
| Indukala, D | 1 |
| Boustani, AM | 1 |
| Patel, V | 1 |
| Cha, CH | 1 |
| Salem, RR | 1 |
| Chang, B | 1 |
| Hochster, HS | 1 |
| Lacy, J | 1 |
| Cravioto-Villanueva, A | 1 |
| Cavazos, M | 1 |
| Luna-Perez, P | 1 |
| Martinez-Gomez, H | 1 |
| Ramirez, ML | 1 |
| Solorzano, J | 1 |
| Montiel, H | 1 |
| Esquivel, J | 5 |
| Chaudhry, NA | 1 |
| Zahid, K | 1 |
| Coman, R | 1 |
| Zhang, Q | 1 |
| Wang, D | 1 |
| Xing, Y | 1 |
| Guo, Y | 1 |
| Suo, J | 1 |
| Chemama, S | 1 |
| Bayar, MA | 1 |
| Lanoy, E | 1 |
| Ammari, S | 1 |
| Stoclin, A | 1 |
| Raynard, B | 7 |
| Antoun, S | 3 |
| Osseis, M | 1 |
| Weyrech, J | 1 |
| Dagois, S | 1 |
| Bhandare, M | 1 |
| Patil, P | 1 |
| Pai, V | 1 |
| Bhamre, R | 1 |
| Engineer, R | 1 |
| Ostwal, V | 1 |
| Díez de Corcuera, I | 1 |
| Manzano, JL | 1 |
| Valladares-Ayerbes, M | 2 |
| Alcaide, J | 1 |
| García García, T | 1 |
| Vera, R | 1 |
| Sastre, J | 1 |
| Yun, Q | 1 |
| Wang, SS | 1 |
| Xu, S | 1 |
| Yang, JP | 1 |
| Fan, J | 1 |
| Yang, LL | 1 |
| Fu, SZ | 1 |
| Wu, JB | 1 |
| Ihemelandu, C | 1 |
| Mehta, AM | 1 |
| Huitema, AD | 1 |
| Burger, JW | 1 |
| Brandt-Kerkhof, AR | 1 |
| van den Heuvel, SF | 1 |
| Verwaal, VJ | 6 |
| Chan, DY | 1 |
| Syn, NL | 1 |
| Yap, R | 1 |
| Phua, JN | 1 |
| Soh, TI | 1 |
| Chee, CE | 1 |
| Nga, ME | 1 |
| So, JB | 1 |
| Shimizu, D | 1 |
| Tanaka, H | 1 |
| Tanaka, C | 1 |
| Kobayashi, D | 2 |
| Hayashi, M | 1 |
| Iwata, N | 1 |
| Niwa, Y | 1 |
| Yamada, S | 1 |
| Sugimoto, H | 2 |
| Murotani, K | 1 |
| Fujiwara, M | 1 |
| Kodera, Y | 2 |
| Sánchez-Velázquez, P | 1 |
| Moosmann, N | 1 |
| Töpel, I | 1 |
| Piso, P | 3 |
| Jouvin, I | 1 |
| Najah, H | 1 |
| Canet Jourdan, C | 1 |
| Mirshahi, M | 1 |
| Tonooka, T | 1 |
| Takiguchi, N | 1 |
| Yamamoto, H | 1 |
| Nabeya, Y | 1 |
| Ikeda, A | 1 |
| Kainuma, O | 1 |
| Soda, H | 1 |
| Imanishi, S | 1 |
| Arimitsu, H | 1 |
| Kobayashi, R | 1 |
| Chibana, T | 1 |
| Ishige, F | 1 |
| Nagata, M | 1 |
| Bruin, S | 1 |
| van Slooten, G | 1 |
| Yasuda, A | 1 |
| Ochi, N | 1 |
| Sakamoto, M | 4 |
| Takayama, S | 1 |
| Wakasugi, T | 1 |
| Funahashi, H | 1 |
| Sawai, H | 1 |
| Satoh, M | 1 |
| Akamo, Y | 2 |
| Takeyama, H | 2 |
| Tibensky, I | 1 |
| Schmidt, J | 1 |
| Ryschich, E | 1 |
| Märten, A | 1 |
| Kitahara, M | 1 |
| Kanekiyo, S | 1 |
| Katayama, S | 1 |
| Lee, JL | 2 |
| Kang, YK | 2 |
| Kang, HJ | 1 |
| Lee, KH | 3 |
| Zang, DY | 1 |
| Ryoo, BY | 1 |
| Kim, JG | 2 |
| Park, SR | 2 |
| Kang, WK | 2 |
| Shin, DB | 1 |
| Ryu, MH | 2 |
| Chang, HM | 2 |
| Kim, TW | 2 |
| Baek, JH | 2 |
| Min, YJ | 1 |
| Farquharson, AL | 1 |
| Pranesh, N | 1 |
| Witham, G | 1 |
| Swindell, R | 1 |
| Taylor, MB | 1 |
| Renehan, AG | 1 |
| Rout, S | 1 |
| Wilson, MS | 1 |
| O'Dwyer, ST | 1 |
| Saunders, MP | 1 |
| Honoré, C | 3 |
| Ciuchendéa, R | 2 |
| Billard, V | 2 |
| Dromain, C | 1 |
| Duvillard, P | 1 |
| Chen, CW | 1 |
| Wang, WM | 1 |
| Su, YC | 1 |
| Wu, JY | 1 |
| Hsieh, JS | 2 |
| Wang, JY | 1 |
| Machida, N | 1 |
| Yoshino, T | 1 |
| Onozawa, Y | 2 |
| Fukutomi, A | 2 |
| Yamazaki, K | 3 |
| Taku, K | 2 |
| Asaka, M | 1 |
| Yan, TD | 5 |
| Wada, A | 1 |
| Fujita, S | 2 |
| Watanabe, Y | 3 |
| Kabuto, T | 2 |
| Chen, CF | 1 |
| Huang, CJ | 1 |
| Kang, WY | 1 |
| Yoshida, N | 1 |
| Kochi, M | 1 |
| Niide, O | 1 |
| Mamiya, T | 1 |
| Mochizuki, S | 1 |
| Ohkubo, T | 1 |
| Takayama, T | 2 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Lee, KW | 1 |
| Song, HS | 1 |
| Lee, NS | 1 |
| Choi, IS | 1 |
| Lee, MH | 1 |
| Kim, MA | 1 |
| Kim, WH | 1 |
| Bang, YJ | 1 |
| Kim, TY | 1 |
| Kim, SH | 3 |
| Kwon, HC | 3 |
| Oh, SY | 3 |
| Lee, DM | 2 |
| Lee, S | 3 |
| Lee, JH | 2 |
| Roh, MS | 1 |
| Kim, DC | 1 |
| Park, KJ | 1 |
| Choi, HJ | 1 |
| Kim, HJ | 3 |
| Novarino, A | 2 |
| Satolli, MA | 2 |
| Chiappino, I | 2 |
| Giacobino, A | 3 |
| Bellone, G | 2 |
| Rahimi, F | 1 |
| Milanesi, E | 1 |
| Bertetto, O | 2 |
| Ciuffreda, L | 3 |
| Huh, JW | 1 |
| Kim, YJ | 1 |
| Kim, HR | 1 |
| Schomas, DA | 1 |
| Miller, RC | 1 |
| Donohue, JH | 1 |
| Thurmes, PJ | 1 |
| Haddock, MG | 1 |
| Quevedo, JF | 1 |
| Gunderson, LL | 1 |
| Gómez Portilla, A | 1 |
| Cendoya, I | 1 |
| Olabarría, I | 1 |
| Martínez de Lecea, C | 1 |
| Gómez Martínez de Lecea, C | 1 |
| Gil, A | 1 |
| Martín, E | 1 |
| Muriel, J | 1 |
| Magrach, L | 1 |
| Romero, E | 1 |
| Lirola, A | 1 |
| Guede, N | 1 |
| Moraza, N | 1 |
| Fernández, E | 1 |
| Kvadatze, M | 1 |
| Valdovinos, M | 1 |
| Larrabide, I | 1 |
| Ruiz de Alegría, N | 1 |
| Fernández, JL | 1 |
| Castillo, C | 1 |
| Rua, O | 1 |
| Ulibarrena, MA | 1 |
| Mitchell, A | 1 |
| Drolet, P | 1 |
| Leblanc, G | 1 |
| Leclerc, YE | 1 |
| Vizio, B | 1 |
| Brondino, G | 1 |
| Addeo, A | 1 |
| Prati, A | 1 |
| Campra, D | 1 |
| Fronda, GR | 1 |
| Yamai, H | 1 |
| Sawada, N | 1 |
| Seike, J | 1 |
| Takizawa, H | 1 |
| Kenzaki, K | 1 |
| Miyoshi, T | 1 |
| Kondo, K | 3 |
| Bando, Y | 1 |
| Ohnishi, Y | 1 |
| Tangoku, A | 2 |
| Chau, I | 2 |
| Ashley, S | 1 |
| Cunningham, D | 3 |
| Sun, WL | 1 |
| Hutarew, G | 1 |
| Gradl, J | 1 |
| Gratzl, M | 1 |
| Denz, H | 1 |
| Fiegl, M | 1 |
| Wagner, M | 1 |
| Roh, V | 1 |
| Strehlen, M | 1 |
| Laemmle, A | 1 |
| Stroka, D | 1 |
| Egger, B | 1 |
| Trochsler, M | 1 |
| Hunt, KK | 1 |
| Candinas, D | 1 |
| Vorburger, SA | 1 |
| Gramann, T | 1 |
| Matter, L | 1 |
| Pfofe, D | 1 |
| Flury, R | 1 |
| Jaeger, P | 1 |
| Kim, BG | 1 |
| Kim, SG | 1 |
| Kim, DK | 1 |
| Jang, JS | 2 |
| Kim, MC | 2 |
| Masellis, AM | 1 |
| Sielaff, TD | 1 |
| Bender, GP | 1 |
| Imazawa, M | 1 |
| Kojima, T | 1 |
| Azad, A | 1 |
| Chionh, F | 1 |
| Jayarajan, J | 1 |
| Kim, ST | 2 |
| Lee, J | 1 |
| Lee, KT | 1 |
| Lee, JK | 1 |
| Choi, SH | 1 |
| Heo, JS | 1 |
| Choi, DW | 1 |
| Lim, HY | 1 |
| Park, YS | 1 |
| Sym, SJ | 1 |
| Yook, JH | 1 |
| Oh, ST | 1 |
| Kim, BS | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 1 |
| Tjulandin, SA | 1 |
| Costes, L | 1 |
| Gauthier, M | 1 |
| Malka, D | 5 |
| Locher, C | 1 |
| Mitry, E | 1 |
| Tougeron, D | 1 |
| Lecomte, T | 1 |
| Gornet, JM | 1 |
| Sobhani, I | 1 |
| Moulin, V | 1 |
| Afchain, P | 1 |
| Taïeb, J | 1 |
| Bonnetain, F | 1 |
| Aparicio, T | 1 |
| Gilly, F | 1 |
| Bereder, JM | 1 |
| Mansvelt, B | 1 |
| Lorimier, G | 1 |
| Ba, MC | 1 |
| Cui, SZ | 1 |
| Lin, SQ | 1 |
| Tang, YQ | 1 |
| Wu, YB | 1 |
| Wang, B | 1 |
| Zhang, XL | 1 |
| Lorenzen, S | 1 |
| Panzram, B | 1 |
| Rosenberg, R | 1 |
| Nekarda, H | 1 |
| Becker, K | 1 |
| Schenk, U | 1 |
| Höfler, H | 1 |
| Siewert, JR | 1 |
| Jäger, D | 1 |
| Ott, K | 1 |
| Rao, S | 1 |
| Starling, N | 1 |
| Sumpter, K | 1 |
| Gilligan, D | 1 |
| Ruhstaller, T | 1 |
| Wilke, H | 1 |
| Archer, C | 1 |
| Kurek, R | 1 |
| Beadman, C | 1 |
| Oates, J | 1 |
| Liauw, W | 3 |
| Koong, HN | 1 |
| Ripley, RT | 1 |
| Davis, JL | 1 |
| Kemp, CD | 1 |
| Wang, GP | 1 |
| Guan, YS | 1 |
| Jin, XR | 1 |
| Jiang, SS | 1 |
| Lu, ZJ | 1 |
| Wu, Y | 1 |
| Li, M | 1 |
| Luo, F | 2 |
| Ryan, DP | 1 |
| Engelman, JA | 1 |
| Ferrone, CR | 1 |
| Sahani, DV | 1 |
| Lisovsky, M | 1 |
| Gong, C | 2 |
| Yang, L | 1 |
| Wu, Q | 2 |
| Shi, S | 1 |
| Shi, H | 1 |
| Qian, Z | 2 |
| Wei, Y | 1 |
| Al-Zahrani, A | 1 |
| Saxena, A | 1 |
| Bijelic, L | 3 |
| Chang, D | 6 |
| Yoo, D | 2 |
| Tamura, T | 2 |
| Ishikawa, N | 1 |
| Koui, S | 1 |
| Nakashima, H | 1 |
| Minagawa, N | 1 |
| Hachiya, Y | 1 |
| Hirata, K | 2 |
| Sako, T | 1 |
| Fukuyama, T | 1 |
| Hirano, Y | 1 |
| Van der Speeten, K | 3 |
| Stuart, OA | 4 |
| Kato, K | 3 |
| Hamaguchi, T | 2 |
| Kim, KH | 1 |
| Kwon, KA | 1 |
| Lee, HS | 1 |
| Doerfer, J | 1 |
| Chun, CL | 1 |
| Eisenstat, S | 1 |
| Dormady, S | 1 |
| Lombard, C | 1 |
| Triadafilopoulos, G | 1 |
| Choi, YJ | 2 |
| Park, KH | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Shin, SW | 1 |
| Kim, JS | 1 |
| Kim, YH | 1 |
| Ito, S | 1 |
| Sawaki, A | 1 |
| Tajika, M | 2 |
| Yokota, T | 1 |
| Ocvirk, J | 1 |
| Reberšek, M | 1 |
| Skof, E | 1 |
| Hlebanja, Z | 1 |
| Boc, M | 1 |
| Klaver, YL | 4 |
| de Hingh, IH | 4 |
| Bae, WK | 1 |
| Lee, SJ | 1 |
| Park, MS | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Cho, SH | 1 |
| Guo, DD | 1 |
| Cho, CS | 1 |
| Park, IK | 1 |
| Chung, IJ | 1 |
| Takiguchi, S | 4 |
| Nakajima, K | 2 |
| Miyata, H | 2 |
| Yamasaki, M | 1 |
| Kurokawa, Y | 1 |
| Okada, K | 2 |
| Mori, M | 2 |
| Doki, Y | 3 |
| Mehta, SS | 1 |
| Roca, L | 1 |
| Hessissen, M | 1 |
| Saint-Aubert, B | 1 |
| Wang, F | 1 |
| Wang, Z | 1 |
| Zhou, N | 1 |
| An, X | 1 |
| Xu, R | 1 |
| He, Y | 1 |
| Hendriks, T | 1 |
| Lomme, RM | 1 |
| Rutten, HJ | 1 |
| Bleichrodt, RP | 3 |
| Nitzkorski, JR | 1 |
| Farma, JM | 1 |
| Watson, JC | 1 |
| Siripurapu, V | 1 |
| Zhu, F | 1 |
| Matteotti, RS | 1 |
| Sigurdson, ER | 1 |
| Tsai, CC | 1 |
| Chang, CH | 1 |
| Chen, LC | 1 |
| Chang, YJ | 1 |
| Lan, KL | 1 |
| Wu, YH | 1 |
| Liu, IH | 1 |
| Ho, CL | 1 |
| Lee, WC | 1 |
| Ni, HC | 1 |
| Chang, TJ | 1 |
| Ting, G | 1 |
| Lee, TW | 1 |
| Franko, J | 1 |
| Shi, Q | 1 |
| Goldman, CD | 1 |
| Pockaj, BA | 1 |
| Nelson, GD | 1 |
| Goldberg, RM | 1 |
| Pitot, HC | 1 |
| Grothey, A | 1 |
| Alberts, SR | 1 |
| Sargent, DJ | 1 |
| Yonemura, Y | 4 |
| Ishibashi, H | 1 |
| Sako, S | 1 |
| Kitai, T | 1 |
| Mizumoto, A | 1 |
| Hirano, M | 1 |
| Ichinose, M | 1 |
| Takao, N | 1 |
| Matsuda, N | 1 |
| Togawa, T | 2 |
| Ozamto, Y | 1 |
| Chang-Yun, L | 1 |
| Elnemr, A | 1 |
| Xiao-Jun, Y | 1 |
| Kuwabara, H | 1 |
| Baba, H | 4 |
| Wakabayashi, M | 1 |
| Nakamura, H | 1 |
| Sanada, T | 1 |
| Goseki, N | 1 |
| Mizota, A | 1 |
| Matsuo, K | 1 |
| Kondo, C | 1 |
| D'Hoore, A | 1 |
| Van Cutsem, E | 1 |
| Fieuws, S | 1 |
| Peeters, M | 1 |
| Bertrand, C | 1 |
| Legendre, H | 1 |
| Kerger, J | 1 |
| Weber, T | 1 |
| Roitman, M | 1 |
| Link, KH | 2 |
| Wang, C | 1 |
| Zhang, D | 1 |
| Woods, R | 1 |
| Larkin, JO | 1 |
| Muldoon, C | 1 |
| Kennedy, MJ | 1 |
| Mehigan, B | 1 |
| McCormick, P | 1 |
| Simkens, LH | 1 |
| Lemmens, VE | 1 |
| Teerenstra, S | 1 |
| Punt, CJ | 1 |
| Tanaka, K | 2 |
| Hirai, K | 1 |
| Ogawa, H | 1 |
| Toya, H | 1 |
| Totsuka, O | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 1 |
| Novarino, AM | 1 |
| Napoletano, R | 1 |
| Ceccarelli, M | 1 |
| Ciccone, G | 1 |
| Schena, M | 1 |
| Taira, K | 1 |
| Kusaba, H | 1 |
| Fuse, N | 1 |
| Asano, T | 1 |
| Negita, M | 1 |
| Uemura, T | 1 |
| Takagi, D | 1 |
| Hattori, M | 1 |
| Kamiya, I | 1 |
| Glockzin, G | 1 |
| von Breitenbuch, P | 1 |
| Schlitt, HJ | 2 |
| Inada, K | 1 |
| Maeshiro, T | 1 |
| Seyama, Y | 1 |
| Miyamoto, S | 1 |
| Inoue, S | 1 |
| Umekita, N | 1 |
| Truman, N | 1 |
| Nethercott, D | 1 |
| Tzanis, D | 1 |
| Benhaim, L | 1 |
| Maisano, R | 1 |
| Azzarello, D | 1 |
| Maisano, M | 1 |
| Mafodda, A | 1 |
| Bottari, M | 1 |
| Egitto, G | 1 |
| Nardi, M | 1 |
| Inal, A | 1 |
| Kaplan, MA | 1 |
| Kuçukoner, M | 1 |
| Urakci, Z | 1 |
| Guven, M | 1 |
| Nas, N | 1 |
| Yunce, M | 1 |
| Işikdogan, A | 1 |
| Kornmann, M | 1 |
| Staib, L | 1 |
| Wiegel, T | 1 |
| Kron, M | 1 |
| Henne-Bruns, D | 1 |
| Formentini, A | 1 |
| Francis, WP | 1 |
| Ho, T | 1 |
| Schaub, NP | 1 |
| Alimchandani, M | 1 |
| Quezado, M | 1 |
| Kalina, P | 1 |
| Eberhardt, JS | 1 |
| Hughes, MS | 1 |
| Hassan, R | 1 |
| Bartlett, DL | 2 |
| Libutti, SK | 2 |
| Pingpank, JF | 2 |
| Kammula, US | 1 |
| Phan, GQ | 1 |
| Alexander, HR | 2 |
| Ozturk, MA | 1 |
| Ozveren, O | 1 |
| Cinar, V | 1 |
| Erdik, B | 1 |
| Oyan, B | 1 |
| Yuki, S | 1 |
| Naito, Y | 1 |
| Fukushima, H | 1 |
| Komatsu, Y | 1 |
| Takano, T | 1 |
| Yamauchi, S | 1 |
| Nakagawa, T | 1 |
| Kasahara, M | 1 |
| Ishiba, T | 1 |
| Tamura, N | 1 |
| Nagahara, M | 1 |
| Sato, T | 1 |
| Sugihara, K | 1 |
| Tajima, Y | 1 |
| Ishibashi, K | 2 |
| Matsuzawa, T | 2 |
| Ishiguro, T | 1 |
| Ohsawa, T | 1 |
| Okada, N | 2 |
| Kumamoto, K | 2 |
| Kumagai, Y | 2 |
| Haga, N | 2 |
| Ishida, M | 1 |
| Miyazawa, T | 1 |
| Ebe, K | 1 |
| Koide, N | 1 |
| Fujita, N | 1 |
| Honma, K | 1 |
| Ikarashi, T | 1 |
| Arienti, C | 1 |
| Tesei, A | 1 |
| Verdecchia, GM | 1 |
| Framarini, M | 1 |
| Virzì, S | 1 |
| Grassi, A | 1 |
| Scarpi, E | 1 |
| Turci, L | 1 |
| Silvestrini, R | 1 |
| Amadori, D | 1 |
| Zoli, W | 1 |
| Hatano, S | 1 |
| Iizuka, R | 1 |
| Kakihara, N | 1 |
| Matsumura, H | 1 |
| Takenaka, A | 1 |
| Lee, KD | 1 |
| Liu, TW | 1 |
| Wu, CW | 1 |
| Tiu, CM | 1 |
| Liu, JM | 1 |
| Chung, TR | 1 |
| Chang, JY | 1 |
| Whang-Peng, J | 1 |
| Chen, LT | 1 |
| Rassu, PC | 1 |
| Cassinelli, G | 1 |
| Ronzitti, F | 1 |
| Bronzino, P | 1 |
| Stanizzi, T | 1 |
| Casaccia, M | 1 |
| Yamashita, K | 1 |
| Mikami, Y | 1 |
| Yamamura, M | 1 |
| Kubozoe, T | 1 |
| Urakami, A | 1 |
| Kimoto, M | 1 |
| Tsunoda, T | 1 |
| El Otmany, A | 2 |
| Bonnay, M | 1 |
| Paci, A | 1 |
| Ducreux, M | 4 |
| Lasser, P | 6 |
| Laurent, S | 1 |
| Bourget, P | 1 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Fujiwara, H | 3 |
| Takagane, A | 5 |
| Abe, K | 4 |
| Irinoda, T | 3 |
| Yonezawa, H | 3 |
| Nakaya, T | 3 |
| Oyama, K | 3 |
| Saito, K | 6 |
| Mori, T | 2 |
| Yasuda, T | 3 |
| Monden, M | 4 |
| Hosoya, Y | 1 |
| Nagai, H | 1 |
| Koinuma, K | 1 |
| Yasuda, Y | 1 |
| Kaneko, Y | 1 |
| Mohamed, F | 2 |
| Usuki, H | 1 |
| Ishimura, K | 1 |
| Yachida, S | 2 |
| Hagiike, M | 1 |
| Okano, K | 1 |
| Izuishi, K | 1 |
| Karasawa, Y | 1 |
| Goda, F | 1 |
| Maeta, H | 1 |
| Kanzaki, N | 1 |
| Ohtani, S | 3 |
| Nemoto, T | 1 |
| Hoshino, Y | 1 |
| Kogure, M | 1 |
| LINDEBOOM, GA | 1 |
| Feldman, AL | 1 |
| Beresnev, TH | 1 |
| Mavroukakis, SM | 1 |
| Liewehr, DJ | 1 |
| Kleiner, DE | 1 |
| Larsson, B | 1 |
| Sundin, A | 1 |
| Khamis, H | 1 |
| Hansson, J | 1 |
| Berglund, A | 1 |
| Påhlman, L | 2 |
| Ruth, SV | 1 |
| Zoetmulder, FA | 6 |
| Gething, S | 1 |
| Haiba, M | 1 |
| Brun, EA | 1 |
| Rischin, D | 1 |
| Phillips, KA | 1 |
| Friedlander, M | 1 |
| Harnett, P | 1 |
| Quinn, M | 1 |
| Richardson, G | 1 |
| Martin, A | 1 |
| Edè, C | 1 |
| Ben Hassouna, D | 1 |
| Boige, V | 3 |
| Côté, JF | 1 |
| Katsumata, K | 1 |
| Ichimiya, H | 1 |
| Wakana, Y | 1 |
| Aoki, T | 1 |
| Delperro, JR | 1 |
| Benhamou, E | 1 |
| Baton, O | 1 |
| Giovannini, M | 1 |
| Oman, M | 1 |
| Tölli, J | 1 |
| Naredi, P | 1 |
| Hafström, LO | 1 |
| van Ruth, S | 1 |
| Ema, T | 1 |
| Arai, K | 5 |
| Maeda, Y | 1 |
| Iwasaki, Y | 4 |
| Katayanagi, S | 1 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Takahashi, T | 5 |
| Fukuda, Y | 1 |
| Fujio, N | 1 |
| Ihara, T | 1 |
| Terakura, M | 1 |
| Takatori, H | 1 |
| Tsukazaki, T | 1 |
| Koyama, I | 1 |
| Tsukazaki, Y | 1 |
| Osugi, H | 1 |
| Yamao, T | 1 |
| Ikeda, N | 1 |
| Saito, H | 3 |
| Iwase, H | 1 |
| Tsuji, Y | 1 |
| Yamamoto, S | 2 |
| Yoshida, S | 3 |
| Hribaschek, A | 2 |
| Pross, M | 2 |
| Ridwelski, K | 2 |
| Meyer, F | 1 |
| Fenske, A | 1 |
| Krüger, S | 1 |
| Lippert, H | 2 |
| Norman, AR | 1 |
| Waters, JS | 1 |
| Topham, C | 1 |
| Middleton, G | 1 |
| Hill, M | 1 |
| Ross, PJ | 1 |
| Katopodis, R | 1 |
| Stewart, G | 1 |
| Oates, JR | 1 |
| Guglielmi, A | 1 |
| Barni, S | 1 |
| Zaniboni, A | 1 |
| Pella, N | 1 |
| Belvedere, O | 1 |
| Beretta, GD | 1 |
| Grossi, F | 1 |
| Frontini, L | 1 |
| Puglisi, F | 1 |
| Labianca, R | 1 |
| Sobrero, A | 1 |
| Iversen, LH | 2 |
| Rasmussen, PC | 2 |
| Wara, P | 1 |
| Buhl, L | 1 |
| Ambrose, NS | 1 |
| Laurberg, S | 2 |
| Yamagata, S | 2 |
| Nakata, B | 1 |
| Hirakawa, K | 1 |
| Güner, Z | 1 |
| Schmidt, U | 1 |
| Dahlke, MH | 1 |
| Klempnauer, J | 1 |
| Nikkuni, K | 1 |
| Nagahashi, M | 1 |
| Makino, S | 2 |
| Nishimura, A | 1 |
| Kawachi, Y | 1 |
| Baba, T | 1 |
| Mandai, M | 1 |
| Fujii, S | 1 |
| Mochizuki, R | 1 |
| Gunji, Y | 1 |
| Takayama, W | 1 |
| Miyazaki, S | 1 |
| Makino, H | 1 |
| Matsushita, K | 1 |
| Miyauchi, H | 1 |
| Chiba, S | 1 |
| Ochiai, T | 1 |
| Tamesa, T | 1 |
| Yoshimura, K | 1 |
| Mori, N | 1 |
| Hazama, S | 1 |
| Oka, M | 1 |
| Matsuda, M | 1 |
| Amemiya, H | 1 |
| Kono, H | 1 |
| Chang, MS | 1 |
| Izawa, S | 1 |
| Furuya, S | 1 |
| Takano, A | 1 |
| Matsumoto, Y | 1 |
| Fujii, H | 1 |
| Shimizu, Y | 2 |
| Sugiyama, S | 2 |
| Miyade, Y | 2 |
| Kecmanovic, DM | 1 |
| Pavlov, MJ | 1 |
| Ceranic, MS | 1 |
| Sepetkovski, AV | 1 |
| Kovacevic, PA | 1 |
| Stamenkovic, AB | 1 |
| Garcia, AA | 1 |
| Blessing, JA | 1 |
| Lenz, HJ | 1 |
| Darcy, KM | 1 |
| Mannel, RS | 1 |
| Miller, DS | 1 |
| Husseinzadeh, N | 1 |
| Todo, T | 1 |
| Zhao, G | 1 |
| Kuroki, S | 1 |
| Cohen, JB | 1 |
| Glorioso, JC | 1 |
| Tanaka, M | 2 |
| González-Moreno, S | 1 |
| Brun, E | 1 |
| Ishikawa, T | 2 |
| Mizuno, K | 1 |
| Togashi, T | 1 |
| Seki, K | 1 |
| Kamimura, T | 1 |
| Comella, P | 1 |
| Massidda, B | 1 |
| Palmeri, S | 1 |
| Farris, A | 1 |
| Lucia, LD | 1 |
| Natale, D | 1 |
| Maiorino, L | 1 |
| Tafuto, S | 1 |
| Cataldis, GD | 1 |
| Casaretti, R | 1 |
| Laplanche, A | 1 |
| Estphan, G | 1 |
| Eimermacher, A | 1 |
| Siebler, J | 1 |
| Höhler, T | 1 |
| Wein, A | 1 |
| Menges, M | 1 |
| Flieger, D | 1 |
| Junginger, T | 1 |
| Geer, T | 1 |
| Gracien, E | 1 |
| Galle, PR | 1 |
| Heike, M | 1 |
| Tanaka, N | 2 |
| Ooka, M | 1 |
| Okajima, S | 1 |
| Liberale, G | 1 |
| Sabourin, JC | 1 |
| Nishida, K | 1 |
| Fujiwara, R | 1 |
| Kodama, Y | 2 |
| Fumoto, S | 1 |
| Mukai, T | 1 |
| Nakashima, M | 1 |
| Sasaki, H | 2 |
| Nakamura, J | 1 |
| Kyser, K | 1 |
| Bidus, MA | 1 |
| Rodriguez, M | 1 |
| Rose, GS | 1 |
| Elkas, JC | 1 |
| Tsuburaya, A | 1 |
| Kobayashi, O | 1 |
| Gusella, M | 1 |
| Rebeschini, M | 1 |
| Cartei, G | 2 |
| Ferrazzi, E | 1 |
| Ferrari, M | 1 |
| Padrini, R | 1 |
| Innis, M | 1 |
| Sandiford, N | 1 |
| Shenoy, RK | 1 |
| Prussia, PR | 1 |
| Zbar, A | 1 |
| Endou, Y | 2 |
| Tochiori, S | 1 |
| Bando, E | 1 |
| Kawamura, T | 1 |
| Shimada, T | 1 |
| Miyamoto, K | 1 |
| Sasaki, T | 4 |
| Bamba, T | 1 |
| Kanda, T | 3 |
| Ohashi, M | 1 |
| Hanyu, T | 1 |
| Yajima, K | 1 |
| Kosugi, S | 1 |
| Hatakeyama, K | 1 |
| Koppe, MJ | 1 |
| Boerman, OC | 1 |
| Oyen, WJ | 1 |
| Wolf, JK | 1 |
| Bodurka, DC | 1 |
| Verschraegen, C | 1 |
| Sun, CC | 1 |
| Branham, D | 1 |
| Jenkins, AD | 1 |
| Atkinson, N | 1 |
| Gershenson, DM | 1 |
| Alderman, R | 1 |
| Edwards, G | 1 |
| Marquardt, CE | 1 |
| Ceelen, WP | 1 |
| Carneiro, BA | 1 |
| Kaminer, L | 1 |
| Eldibany, M | 1 |
| Sreekantaiah, C | 1 |
| Kaul, K | 1 |
| Locker, GY | 1 |
| Hasegawa, S | 1 |
| Mukai, M | 1 |
| Sato, S | 1 |
| Ninomiya, H | 1 |
| Wakui, K | 1 |
| Komatsu, N | 1 |
| Tajima, T | 1 |
| Nakasaki, H | 1 |
| Makuuchi, H | 1 |
| Yu, W | 2 |
| Bandou, E | 1 |
| Sawa, T | 1 |
| Yoshimitsu, Y | 1 |
| Jeon, SB | 1 |
| Chae, YS | 1 |
| Kim, DH | 1 |
| Sohn, SK | 1 |
| Lee, KB | 1 |
| Shin, HJ | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Jung, HY | 1 |
| Oshima, T | 2 |
| Yamada, R | 1 |
| Hatori, S | 1 |
| Kunisaki, C | 1 |
| Imada, T | 1 |
| Kanamaru, T | 1 |
| Yamamoto, M | 2 |
| Links, M | 2 |
| Xu, ZY | 1 |
| Kam, PC | 1 |
| Glenn, D | 1 |
| Yilmaz, U | 1 |
| Oztop, I | 1 |
| Alacacioglu, A | 1 |
| Yaren, A | 1 |
| Tarhan, O | 1 |
| Somali, I | 1 |
| Honda, I | 1 |
| Farkhondeh, F | 1 |
| Rouquie, D | 1 |
| Benizri, E | 1 |
| Di Pietrantonio, D | 2 |
| Menegon, P | 1 |
| Tanabe, S | 1 |
| Koizumi, W | 1 |
| Higuchi, K | 1 |
| Nakatani, K | 1 |
| Shimoda, T | 1 |
| Nishimura, K | 1 |
| Kobayashi, N | 1 |
| Mitomi, H | 1 |
| Saigenji, K | 1 |
| da Silva, RG | 1 |
| Pérez, J | 1 |
| Rodríguez, MJ | 1 |
| Campaña, O | 1 |
| Veiras, S | 1 |
| Lorenzo, D | 1 |
| Lamas, M | 1 |
| Alvarez, J | 1 |
| Blot, F | 2 |
| Kohneh-Shahri, N | 2 |
| Dang, A | 1 |
| Mansfield, P | 1 |
| Ilsin, B | 1 |
| Hightower, C | 1 |
| Aravindan, N | 1 |
| Rice, D | 1 |
| Riedel, B | 1 |
| Ember, A | 1 |
| Yousuf, AF | 1 |
| Kalmár, K | 1 |
| Papp, A | 1 |
| Esik, O | 1 |
| Horváth, OP | 1 |
| Fransi, S | 1 |
| Jacques, T | 1 |
| Black, D | 1 |
| Saunders, V | 1 |
| Miyake, Y | 1 |
| Shiraha, H | 1 |
| Sakaguchi, K | 1 |
| Shiratori, Y | 1 |
| Yamada, E | 1 |
| Nishizaki, M | 1 |
| Takakura, N | 1 |
| von Heideman, A | 1 |
| Grundmark, B | 1 |
| Tholander, B | 1 |
| Bilancia, D | 1 |
| Germano, D | 1 |
| Dinota, A | 1 |
| Romano, R | 1 |
| Reggiardo, G | 1 |
| Manzione, L | 1 |
| Folprecht, G | 1 |
| Köhne, CH | 1 |
| Lutz, MP | 1 |
| Yamamitsu, S | 1 |
| Kimura, H | 1 |
| Inui, N | 1 |
| Hiyama, S | 1 |
| Kimura, Y | 1 |
| Shirasaka, T | 1 |
| Hayashi, Y | 1 |
| Akiyama, J | 1 |
| Watanabe, M | 1 |
| Nozaki, Y | 1 |
| Iwashita, R | 1 |
| Nagaoki, Y | 1 |
| Sakurai, T | 2 |
| Nagata, N | 1 |
| Yago, Y | 1 |
| Sako, A | 1 |
| Kobayakawa, M | 1 |
| Tamegai, Y | 1 |
| Masaki, N | 1 |
| Uemura, N | 1 |
| Umeda, N | 1 |
| Yamazaki, M | 1 |
| Nishida, T | 1 |
| Jess, P | 1 |
| Nielsen, MB | 1 |
| Hansen, F | 1 |
| Tani, M | 1 |
| Miyazawa, M | 1 |
| Hirono, S | 1 |
| Ina, S | 1 |
| Nishioka, R | 1 |
| Fujita, Y | 1 |
| Uchiyama, K | 1 |
| Yamaue, H | 1 |
| Boulet, T | 1 |
| Bonnet, S | 1 |
| Kim, MM | 1 |
| Das, P | 1 |
| Janjan, NA | 1 |
| Badgwell, BD | 1 |
| Phan, AT | 1 |
| Delclos, ME | 1 |
| Maru, D | 1 |
| Ajani, JA | 1 |
| Crane, CH | 1 |
| Krishnan, S | 1 |
| Takayanagi, H | 1 |
| Karaki, H | 1 |
| Suzuki, H | 1 |
| Hayashi, S | 1 |
| Yamamoto, K | 2 |
| Yamamori, H | 1 |
| Sugano, I | 1 |
| Unno, T | 1 |
| Sugawa, T | 1 |
| Harvey, VJ | 1 |
| Slevin, ML | 1 |
| Ponder, BA | 1 |
| Blackshaw, AJ | 1 |
| Wrigley, PF | 1 |
| Fornasiero, A | 1 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Richter, B | 1 |
| Richter, P | 1 |
| Buchholz, K | 1 |
| Kano, T | 1 |
| Tamada, R | 1 |
| Abe, Y | 1 |
| Hiramoto, Y | 1 |
| Notsuka, T | 1 |
| Shiraishi, M | 1 |
| Inoue, F | 2 |
| Kumashiro, R | 1 |
| Inokuchi, K | 1 |
| Smith, WE | 1 |
| Hubert, DD | 1 |
| Holiat, SM | 1 |
| Sobel, HJ | 1 |
| Davis, S | 1 |
| Speyer, JL | 1 |
| Myers, CE | 2 |
| Takamatsu, S | 2 |
| Maruyama, M | 3 |
| Sugano, N | 3 |
| Katada, M | 1 |
| Ebuchi, M | 3 |
| Kawano, K | 1 |
| Inokuchi, T | 1 |
| Fujihara, T | 1 |
| Mori, F | 1 |
| Yoshioka, Y | 1 |
| Tamura, Y | 1 |
| Kimoto, K | 1 |
| Sawada, K | 1 |
| Tan, M | 1 |
| Kanno, M | 1 |
| Saitou, K | 1 |
| Oikawa, K | 1 |
| Shibuya, S | 1 |
| Fukura, Y | 1 |
| Nakamura, M | 1 |
| Kikuchi, T | 1 |
| Hatakeyoma, F | 1 |
| Kuzuya, T | 2 |
| Yamauchi, M | 2 |
| Ito, A | 2 |
| Hasegawa, M | 2 |
| Hasegawa, T | 1 |
| Nabeshima, T | 1 |
| Shibata, N | 1 |
| Tamai, M | 1 |
| Ikeda, K | 3 |
| Massad, LS | 1 |
| Wagley, E | 1 |
| Winkelman, L | 1 |
| Lincoln, S | 1 |
| Yordan, EL | 1 |
| de Geest, K | 1 |
| Wilbanks, GD | 1 |
| Sullivan, MH | 1 |
| Mizumoto, K | 1 |
| Sawada, T | 1 |
| Furumoto, T | 1 |
| Kawamura, Y | 2 |
| Katoh, K | 1 |
| Jablonski, KA | 1 |
| Rexroth, G | 1 |
| Scotland, V | 1 |
| Zhang, GJ | 1 |
| Adachi, I | 1 |
| Yin, DF | 1 |
| Narabayashi, M | 1 |
| Tokue, Y | 1 |
| Watanabe, T | 1 |
| Kaneko, A | 1 |
| Tsuda, H | 1 |
| Okizuka, H | 1 |
| Kaji, Y | 1 |
| Ishida, T | 1 |
| Iwanari, O | 1 |
| Kitao, M | 1 |
| Kosaka, T | 2 |
| Sugaya, J | 2 |
| Sejima, T | 1 |
| Takano, Y | 1 |
| Nakano, Y | 2 |
| Akiyama, T | 2 |
| Kiriyama, M | 1 |
| Tomita, F | 2 |
| Kita, I | 2 |
| Fujimura, T | 1 |
| Fujita, H | 1 |
| Hasebe, K | 1 |
| Kaji, M | 1 |
| Nakai, M | 1 |
| Ninomiya, I | 1 |
| Sahara, H | 1 |
| Kurita, A | 3 |
| Takashima, S | 4 |
| Doihara, H | 2 |
| Mio, H | 1 |
| Terabe, K | 1 |
| Prat, F | 1 |
| Chapelon, JY | 1 |
| el Fadil, FA | 1 |
| Theillère, Y | 1 |
| Ponchon, T | 1 |
| Cathignol, D | 1 |
| Eatock, MM | 1 |
| Carlin, W | 1 |
| Dunlop, DJ | 1 |
| Soukop, M | 1 |
| Watson, DG | 1 |
| Estes, NC | 1 |
| Giri, S | 1 |
| Fabian, C | 1 |
| Murase, M | 1 |
| Yokoyama, Y | 1 |
| Kato, J | 1 |
| Hibi, K | 1 |
| Kasai, Y | 1 |
| Akiyama, S | 1 |
| Ito, K | 2 |
| Koslowe, P | 2 |
| Tsuchiya, K | 1 |
| Sasaki, A | 2 |
| Okamoto, K | 2 |
| Takiyama, I | 2 |
| Kuboi, M | 1 |
| Sasaki, N | 2 |
| Willett, CG | 1 |
| Daly, WJ | 1 |
| Warshaw, AL | 1 |
| Hagiwara, A | 2 |
| Sawai, K | 1 |
| Sakakura, C | 2 |
| Tsujimoto, H | 1 |
| Imanishi, T | 1 |
| Ohgaki, M | 1 |
| Yamazaki, J | 1 |
| Muranishi, S | 2 |
| Yamamoto, A | 1 |
| Fujita, T | 1 |
| Ronnett, BM | 1 |
| Archer, A | 1 |
| Averbach, AM | 1 |
| Bland, R | 1 |
| Dalton, RR | 1 |
| Ettinghausen, SE | 1 |
| Jacquet, P | 1 |
| Jelinek, J | 1 |
| Kurman, RJ | 1 |
| Shmookler, B | 1 |
| Stephens, AD | 1 |
| Steves, MA | 1 |
| White, S | 1 |
| Zahn, CM | 1 |
| Kubo, Y | 1 |
| Saeki, T | 1 |
| Yokoyama, N | 2 |
| Tanada, M | 2 |
| Takiyama, W | 2 |
| Saeki, H | 2 |
| Kerr, DJ | 1 |
| Young, AM | 1 |
| Neoptolemos, JP | 1 |
| Sherman, M | 1 |
| Van-Geene, P | 1 |
| Stanley, A | 1 |
| Ferry, D | 1 |
| Dobbie, JW | 2 |
| Vincke, B | 1 |
| Gilbert, J | 1 |
| el Eini, D | 1 |
| Dombros, N | 1 |
| Fountzilas, G | 1 |
| Chung, YC | 1 |
| Huang, MT | 1 |
| Chang, CN | 1 |
| Huang, TW | 1 |
| Kitamura, M | 4 |
| Nishiyama, M | 1 |
| Toge, T | 1 |
| Civalleri, D | 1 |
| Esposito, M | 1 |
| De Cian, F | 1 |
| Balletto, N | 1 |
| Vannozzi, MO | 1 |
| Mondini, G | 1 |
| Carrabetta, S | 1 |
| Bocchio, MM | 1 |
| Endo, M | 1 |
| Yuasa, Y | 1 |
| Tsujinaka, T | 1 |
| Shiozaki, H | 1 |
| Inoue, M | 1 |
| Taniguchi, M | 1 |
| Murata, A | 1 |
| Tsushima, K | 1 |
| Sakata, Y | 1 |
| Shirasu, M | 1 |
| Yamasaki, J | 1 |
| Hyon, S | 1 |
| Ikada, Y | 1 |
| Nagahama, T | 1 |
| Hiratsuka, M | 1 |
| Furukawa, H | 1 |
| Nakano, H | 1 |
| Ohigashi, H | 1 |
| Kameyama, M | 1 |
| Sasaki, Y | 1 |
| Ishikawa, O | 1 |
| Imaoka, S | 1 |
| Tsuji, A | 1 |
| Takasaki, M | 1 |
| Morita, S | 1 |
| Takamatsu, M | 1 |
| Horimi, T | 1 |
| Takahashi, I | 1 |
| Arnaud, JP | 1 |
| Onda, T | 1 |
| Yoshikawa, H | 1 |
| Yasugi, T | 1 |
| Mishima, M | 1 |
| Nakagawa, S | 1 |
| Yamada, M | 1 |
| Matsumoto, K | 1 |
| Taketani, Y | 1 |
| El-Attar, AF | 1 |
| Skeel, RT | 1 |
| Howard, JM | 1 |
| Funahashi, Y | 1 |
| Koyanagi, N | 1 |
| Sonoda, J | 1 |
| Kitoh, K | 1 |
| Yoshimatsu, K | 1 |
| Ohnuma, S | 1 |
| Takenami, K | 1 |
| Ueno, T | 1 |
| Hosch, WP | 1 |
| Rudi, J | 1 |
| Stremmel, W | 1 |
| Cavaliere, F | 2 |
| Di Filippo, F | 2 |
| Cosimelli, M | 2 |
| Aloe, L | 2 |
| Arcuri, E | 2 |
| Anzà, M | 1 |
| Callopoli, A | 2 |
| Di Lauro, L | 1 |
| Morace, E | 1 |
| Botti, C | 2 |
| Natoli, S | 1 |
| Tedesco, M | 2 |
| Giunta, S | 2 |
| Cavaliere, R | 2 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| Clingan, P | 1 |
| King, DW | 1 |
| Araya, M | 1 |
| Shimooki, O | 1 |
| Inaba, T | 1 |
| Nakajima, J | 1 |
| Cellier, C | 1 |
| Yaghi, C | 1 |
| Cuillerier, E | 1 |
| Siauve, N | 1 |
| Berger, A | 1 |
| Carnot, F | 1 |
| Haddad, C | 1 |
| Barbier, JP | 1 |
| Landi, B | 1 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Jibiki, M | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Kataoka, T | 1 |
| Teramoto, K | 1 |
| Iwai, T | 1 |
| Kollmannsberger, C | 1 |
| Quietzsch, D | 1 |
| Haag, C | 1 |
| Lingenfelser, T | 1 |
| Schroeder, M | 1 |
| Baronius, W | 1 |
| Hempel, V | 1 |
| Clemens, M | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Nakagami, K | 1 |
| Sugitani, K | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Ohya, T | 1 |
| Ohwada, S | 1 |
| Morishita, Y | 1 |
| Nakahara, H | 2 |
| Nakahara, M | 1 |
| Asahara, T | 1 |
| Giannarelli, D | 1 |
| Aromatario, C | 1 |
| Consolo, S | 1 |
| Laurenzi, L | 1 |
| Di Angelo, P | 1 |
| Pestieau, SR | 2 |
| Noh, SH | 1 |
| Yoo, CH | 1 |
| Chung, HC | 1 |
| Roh, JK | 1 |
| Min, JS | 1 |
| de Bree, E | 2 |
| Kaag, MM | 2 |
| van Slooten, GW | 2 |
| van Coevorden, F | 2 |
| Yan, H | 1 |
| Shmookler, BM | 1 |
| Beijnen, JH | 1 |
| Maindrault-Goebel, F | 1 |
| de Gramont, A | 2 |
| Louvet, C | 2 |
| André, T | 1 |
| Carola, E | 1 |
| Mabro, M | 1 |
| Artru, P | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Izrael, V | 1 |
| Krulik, M | 2 |
| Rougier, P | 1 |
| Kuroki, Y | 1 |
| Otagiri, S | 1 |
| Tsukada, K | 1 |
| Yamamoto, T | 1 |
| Mutoh, T | 1 |
| Tatematsu, H | 1 |
| Yamataka, K | 1 |
| Kuhn, R | 1 |
| Halangk, W | 1 |
| Boltze, C | 1 |
| Kim, JY | 1 |
| Bae, HS | 1 |
| Teranishi, F | 1 |
| Manabe, T | 1 |
| Schüll, B | 1 |
| Kornek, GV | 1 |
| Scheithauer, W | 1 |
| Tahara, M | 1 |
| Nagashima, F | 1 |
| Muto, M | 1 |
| Sano, Y | 1 |
| Yoshida, M | 1 |
| Mera, K | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Vadiaka, M | 1 |
| Koufos, C | 1 |
| Marchettini, P | 1 |
| Fukushima, N | 1 |
| Matsuno, Y | 1 |
| Kosuge, T | 1 |
| Hirohashi, S | 1 |
| Butterworth, SA | 1 |
| Panton, ON | 1 |
| Klaassen, DJ | 1 |
| Shah, AM | 1 |
| McGregor, GI | 1 |
| Murakami, M | 1 |
| Morikawa, A | 1 |
| Okabe, R | 1 |
| Miyazawa, K | 1 |
| Iijima, S | 1 |
| Ozaki, K | 1 |
| Suzuki, A | 1 |
| Koyama, Y | 1 |
| Sugiyama, A | 1 |
| Ratto, C | 1 |
| Ricci, R | 1 |
| Rossi, C | 1 |
| Morelli, U | 1 |
| Vecchio, FM | 1 |
| Doglietto, GB | 1 |
| Legha, SS | 1 |
| Muggia, FM | 1 |
| Dunnick, NR | 1 |
| Jones, RB | 1 |
| Doppman, JL | 1 |
| Speyer, J | 1 |
| Newman, CE | 1 |
| Ellis, DJ | 1 |
| Battelli, T | 2 |
| Bonsignori, M | 1 |
| Cenci, AM | 1 |
| Giustini, L | 1 |
| Manocchi, P | 2 |
| Verna, G | 1 |
| Creech, RH | 1 |
| Catalano, RB | 1 |
| Mastrangelo, MJ | 1 |
| Engstrom, PF | 1 |
| Kucuksu, N | 1 |
| Thomas, W | 1 |
| Ezdinli, EZ | 1 |
| Congy, F | 1 |
| Pelletier, S | 1 |
| Langlois, P | 1 |
| Khayat, D | 1 |
| Homsi, T | 1 |
| Emerit, J | 1 |
| Nomoto, K | 2 |
| Yokokura, T | 1 |
| Miyashita, K | 2 |
| Nagai, S | 1 |
| Satta, T | 1 |
| Kubo, T | 2 |
| Maruyama, Y | 2 |
| Ridolfi, R | 1 |
| Amaducci, L | 1 |
| Derni, S | 1 |
| Fabbri, L | 1 |
| Innocenti, MP | 1 |
| Vignutelli, P | 1 |
| Ueshima, Y | 1 |
| Takeuchi, K | 1 |
| Oguro, A | 1 |
| Tsukuda, N | 1 |
| Shioaki, Y | 1 |
| Harada, M | 1 |
| Demuynck, B | 1 |
| Nordlinger, B | 1 |
| Maisani, JE | 1 |
| Lagadec, B | 1 |
| Delfau, S | 1 |
| Varette, C | 1 |
| Gonzalez-Canali, G | 1 |
| Landy, D | 1 |
| Jaffe, G | 1 |
| Pascal, R | 1 |
| Soga, H | 1 |
| Moriwaki, S | 1 |
| Graves, T | 1 |
| DeBruijn, EA | 1 |
| Cunliffe, WJ | 1 |
| Mullins, RE | 1 |
| Hull, WE | 1 |
| Oliff, L | 1 |
| Schlag, P | 1 |
| Nagashima, K | 1 |
| Koyanagi, Y | 1 |
| Kusama, K | 1 |
| Ono, M | 1 |
| Nakajima, A | 1 |
| Eiraku, H | 1 |
| Serizawa, H | 1 |
| Ebihara, Y | 1 |
| Kashani-Sabet, M | 1 |
| Lu, Y | 1 |
| Leong, L | 1 |
| Haedicke, K | 1 |
| Scanlon, KJ | 1 |
| Kuwahara, A | 1 |
| Hirao, E | 1 |
| Shimoda, K | 1 |
| Saito, T | 1 |
| Schilsky, RL | 1 |
| Choi, KE | 1 |
| Grayhack, J | 1 |
| Grimmer, D | 1 |
| Guarnieri, C | 1 |
| Fullem, L | 1 |
| Archer, S | 1 |
| Gray, B | 1 |
| Markman, M | 2 |
| Reichman, B | 2 |
| Hakes, T | 2 |
| Hoskins, W | 2 |
| Rubin, S | 2 |
| Jones, W | 1 |
| Lewis, JL | 2 |
| Morere, JF | 1 |
| Delanian, S | 1 |
| Boaziz, C | 1 |
| Breau, JL | 1 |
| Israel, L | 1 |
| Knüsli, C | 1 |
| Ruff, P | 1 |
| Laffer, U | 1 |
| Stoll, HR | 1 |
| Obrist, R | 1 |
| Weber, W | 1 |
| Obrecht, JP | 1 |
| Schwartz, PM | 1 |
| Moir, RD | 1 |
| Hyde, CM | 1 |
| Turek, PJ | 1 |
| Handschumacher, RE | 1 |
| Schneider, T | 1 |
| Lotze, W | 1 |
| Regelson, W | 1 |
| Parker, G | 1 |
| Warrington, RC | 1 |
| Cheng, I | 1 |
| Fang, WD | 1 |
| Kemeny, N | 1 |
| Kelsen, D | 1 |
| Saeed, W | 1 |
| Kim, S | 1 |
| Burch, BH | 1 |
| Limber, GK | 1 |
| King, RE | 1 |
| Silverberg, SG | 1 |
| Gerner, RE | 1 |
| Moore, GE | 1 |
| Lokich, JJ | 1 |
| Brooks, JR | 1 |
| Eiselein, J | 1 |
| Biggs, MW | 1 |
| Yoshikawa, K | 1 |
| Kitaoka, H | 1 |
| Matsui, K | 1 |
| Davis, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study[NCT02826486] | Phase 2 | 80 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375] | 400 participants (Anticipated) | Observational | 2019-09-01 | Recruiting | |||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700] | Phase 2 | 55 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | ||
| Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial[NCT00941655] | Phase 3 | 15 participants (Actual) | Interventional | 2009-07-22 | Completed | ||
| Hyperthermic Intraperitoneal Chemotherapy, Intravenous Chemotherapy Combined With Surgery for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis[NCT02549911] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457] | Phase 2 | 75 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910] | Phase 1 | 36 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | ||
| Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy[NCT04941625] | 150 participants (Anticipated) | Observational | 2018-02-23 | Recruiting | |||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma[NCT00215644] | Phase 2 | 72 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases[NCT01095523] | Phase 2 | 0 participants (Actual) | Interventional | 2010-01-14 | Withdrawn | ||
| Intravital Microscopy (IVM) in Human Solid Tumors[NCT03823144] | 50 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | |||
| Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)[NCT03517852] | 30 participants (Actual) | Interventional | 2018-08-15 | Active, not recruiting | |||
| Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753] | Phase 1 | 14 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Circulating Tumor DNA (ctDNA) as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer: A Prospective, Open-label, Randomized Controlled Study[NCT04752930] | 138 participants (Anticipated) | Interventional | 2020-08-24 | Recruiting | |||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver[NCT00019786] | Phase 2 | 67 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma[NCT01833832] | Phase 2 | 11 participants (Actual) | Interventional | 2013-04-12 | Completed | ||
| Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer[NCT00006812] | Phase 2 | 0 participants | Interventional | 2001-03-31 | Terminated | ||
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285] | 1,500 participants (Anticipated) | Observational [Patient Registry] | 2014-12-31 | Recruiting | |||
| An Interpretative Phenomenological Analysis of 'Recovery' Following Complete Cytoreductive Surgery.[NCT04125225] | 0 participants (Actual) | Observational | 2019-11-01 | Withdrawn (stopped due to No participants enrolled.) | |||
| A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C[NCT05513183] | 74 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis[NCT00001332] | Phase 1 | 50 participants | Interventional | 1992-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 6 |
The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 8 |
Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 36.5 |
Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Percent change (Median) |
|---|---|
| Genistein | -43.0 |
Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 11.5 |
"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 6 | 3 | 2 | 2 |
Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Genistein | 250 | 119 | 24 | 0 |
"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| Genistein | 69 | 38 |
"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 8 | 1 | 2 | 2 |
Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 2 |
| Systemic Chemotherapy Alone | 0 |
Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1
| Intervention | ml (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 650 |
Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours
| Intervention | hours (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 10.1 |
Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks
| Intervention | Days (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 17 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 8 |
| Systemic Chemotherapy Alone | 5 |
CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1
| Intervention | Scores on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1
| Intervention | Stage (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 Before Surgery | Patient 1 After Surgery | Patient 2 Before Surgery | Patient 2 After Surgery | Patient 3 Before Surgery | Patient 3 After Surgery | Patient 4 Before Surgery | Patient 4 After Surgery | Patient 5 Before Surgery | Patient 5 After Surgery | Patient 6 Before Surgery | Patient 6 After Surgery | Patient 7 Before Surgery | Patient 7 After Surgery | Patient 8 Before Surgery | Paitent 8 After Surgery | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 |
Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #4 | Patient #6 | Patient #7 | Patient #9 | Patient #11 | Patient #15 | |
| Surgery + HIPEC + Systemic Chemotherapy | 19 | 11 | 11 | 4 | 14 | 5 | 12 | 0 |
Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #3 | Patient #5 | Patient #8 | Patient #10 | Patient #12 | Patient #13 | Patient #14 | |
| Systemic Chemotherapy Alone | 17 | 6 | 10 | 0 | 0 | 8 | 0 |
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 35.1 |
| LAPC Modified FOLFIRINOX | 17.2 |
Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 81 |
| LAPC Modified FOLFIRINOX | 100 |
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 54 |
| LAPC Modified FOLFIRINOX | 97 |
The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total | Unresectable | Borderline | |
| LAPC Modified FOLFIRINOX | 13 | 6 | 7 |
Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Febrile neutropenia | Diarrhea | Fatigue | Alanine aminotransferase (ALT) increased | Thromboembolic event | Peripheral sensory neuropathy | Vomiting | |
| LAPC Modified FOLFIRINOX | 5 | 2 | 2 | 2 | 4 | 4 | 0 | 0 | 0 | 1 |
| MPC Modified FOLFIRINOX | 4 | 5 | 2 | 1 | 8 | 5 | 3 | 3 | 2 | 1 |
Objective response was defined as having a CR or a PR. Response assessment was performed using modified WHO criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: >50% decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. Duration of objective response was defined as time from first appearance of CR or PR to time of PD (PD: >25% increase in one or more lesions, or appearance new lesions) or death. Duration of objective response was to be assessed using Kaplan-Meier analysis. (NCT00215644)
Timeframe: From first documented objective response to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | NA |
| ECX Only | NA |
OS was defined as the duration from randomization to death (due to any cause). OS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 9.4 |
| ECX Only | 12.2 |
Objective response was defined as having a complete response (CR) or a partial response (PR). Response assessment was performed using modified World Health Organization (WHO) criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: greater than (>) 50 percent (%) decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 31 |
| ECX Only | 58 |
PFS was defined as the time from randomization to the first documentation of PD or to death due to any cause, whichever occurred first. PD: >25% increase in one or more lesions, or appearance new lesions. PFS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 4.8 |
| ECX Only | 7.1 |
EORTC QLQ-C30 included GHS/QoL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from EORTC QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL was linearly transformed and ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). EORTC QLQ-C30 GHS/QoL score at baseline and best overall change from baseline (throughout study) are reported. (NCT00215644)
Timeframe: Baseline (Day 1), Post Baseline (Up to 3 Years)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Post-Baseline | |
| ECX Only | 67.9 | -10.0 |
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 53.3 | 0.0 |
Amount of time subject survives without intraperitoneal disease progression after treatment. Disease progression is defined as imageable tumor nodules or increasing ascites persistent on computed tomography (CT) scan as interpreted by the official interpretation of the imaging studies. (NCT01833832)
Timeframe: Amount of time subject survives without intraperitoneal disease progression after treatment, an average of 17 months
| Intervention | Months (Median) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 19 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01833832)
Timeframe: Date treatment consent signed to date off study, approximately 34 months and 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 8 |
Patients who died following the HIPEC procedure. The HIPEC is a surgical procedure in which two large bore catheters are inserted in the abdominal wall over the liver and pelvis. The physician closes the abdominal fascia and the catheters are connected to a perfusion circuit. The temperature of the catheters is carefully monitored while the physician ensures the perfusion is distributed properly by manually moving the abdomen. (NCT01833832)
Timeframe: Patients were assessed every 3 months up to an average of 17 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 0 |
Percentage of participants who are alive after treatment. (NCT01833832)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 66.7 |
QOL characteristics were collected using The Functional Assessment of Cancer Therapy-Colorectal Quality of Life (QOL) questionnaire version 4, a validated survey that interrogates physical, emotional, functional, and social well being in cancer related issues on a 5-point scale. Scores range from 0 to 108 points. Higher scores are consistent with a better outcome. (NCT01833832)
Timeframe: Prior to surgery, 6 weeks post surgery, and 3 months post surgery
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Prior to surgery | 6 weeks after surgery | 3 months after surgery | |
| Cytoreductive Surgery Followed by HIPEC | 82.6 | 76.4 | 80.2 |
31 reviews available for fluorouracil and Peritoneal Neoplasms
| Article | Year |
|---|---|
After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2022 |
After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2022 |
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto | 2021 |
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto | 2021 |
Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Peritone | 2022 |
Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Peritone | 2022 |
[A case of juvenile colon cancer with peritoneal dissemination treated effectively by use of resection and chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colostomy; C | 2014 |
[A case of juvenile colon cancer with peritoneal dissemination treated effectively by use of resection and chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colostomy; C | 2014 |
[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplas | 2015 |
[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplas | 2015 |
Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; | 2015 |
Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2009 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2009 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2011 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2011 |
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2013 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2013 |
[A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycyt | 2012 |
[A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycyt | 2012 |
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother | 2002 |
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother | 2002 |
[Pseudomyxoma peritonei--a syndrome with varying prognosis].
Topics: Adult; Antimetabolites, Antineoplastic; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Perit | 2003 |
[Pseudomyxoma peritonei--a syndrome with varying prognosis].
Topics: Adult; Antimetabolites, Antineoplastic; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Perit | 2003 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2004 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2004 |
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combined Modality Therapy; Fl | 2006 |
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combined Modality Therapy; Fl | 2006 |
Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Female; Fluor | 2005 |
Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Female; Fluor | 2005 |
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hum | 2006 |
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hum | 2006 |
Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.
Topics: Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Combined Modality The | 2005 |
Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.
Topics: Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Combined Modality The | 2005 |
A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2006 |
A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2006 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; C | 2007 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; C | 2007 |
Eyelid metastasis from breast cancer showing marked response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular | 1995 |
Eyelid metastasis from breast cancer showing marked response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular | 1995 |
Pseudomyxoma peritonei syndrome.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Peritoneal Neoplasms; Prognosis; Pseudomyxoma | 1996 |
Pseudomyxoma peritonei syndrome.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Peritoneal Neoplasms; Prognosis; Pseudomyxoma | 1996 |
Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1997 |
Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1997 |
Selection of adjuvant chemotherapy for gastric cancer using objective criteria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Carcinoembryonic Antigen; Chemotherap | 1997 |
Selection of adjuvant chemotherapy for gastric cancer using objective criteria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Carcinoembryonic Antigen; Chemotherap | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1998 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1998 |
[Treatment of peritoneal carcinosis of colorectal origin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemothe | 1997 |
[Treatment of peritoneal carcinosis of colorectal origin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemothe | 1997 |
Mucinous adenocarcinoma of the small bowel with peritoneal seeding.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Mucinous adenocarcinoma of the small bowel with peritoneal seeding.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Therapeutic approaches in malignant mesothelioma.
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, | 1977 |
Therapeutic approaches in malignant mesothelioma.
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, | 1977 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1986 |
The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1986 |
88 trials available for fluorouracil and Peritoneal Neoplasms
| Article | Year |
|---|---|
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorour | 2021 |
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorour | 2021 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Per | 2023 |
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-U | 2020 |
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-U | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2020 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal N | 2018 |
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal N | 2018 |
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Topics: Adult; Aged; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Do | 2018 |
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Topics: Adult; Aged; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Do | 2018 |
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2019 |
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2019 |
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, random
Topics: Adult; Bevacizumab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cytored | 2019 |
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, random
Topics: Adult; Bevacizumab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cytored | 2019 |
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla | 2019 |
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla | 2019 |
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neo | 2014 |
Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neo | 2014 |
[Prospective multicentric phase III study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Fluorouraci | 2014 |
[Prospective multicentric phase III study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Fluorouraci | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2014 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antige | 2008 |
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antige | 2008 |
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy | 2010 |
Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl | 2011 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl | 2011 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Ad | 2012 |
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Ad | 2012 |
Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Female; Fluorouracil; Hot Temperature; Humans; Hyperthermia, Induc | 2002 |
Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Female; Fluorouracil; Hot Temperature; Humans; Hyperthermia, Induc | 2002 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2004 |
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2004 |
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoma; Cecum | 2004 |
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoma; Cecum | 2004 |
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm | 2004 |
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm | 2004 |
Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Mo | 2004 |
Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Mo | 2004 |
Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colorectal | 2004 |
Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colorectal | 2004 |
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2004 |
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2004 |
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; | 2004 |
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2005 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose | 2005 |
Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagog | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagog | 2005 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecita | 2006 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecita | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2006 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2006 |
Peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Co | 2006 |
Peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Co | 2006 |
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Parente | 2007 |
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Parente | 2007 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2007 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
[Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; F | 2007 |
[Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; F | 2007 |
[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1995 |
[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1995 |
[Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer].
Topics: Adult; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Services, Ho | 1994 |
[Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer].
Topics: Adult; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Services, Ho | 1994 |
[Home chemotherapy for peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubi | 1994 |
[Home chemotherapy for peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubi | 1994 |
Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy.
Topics: Absorption; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chromatog | 1994 |
Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy.
Topics: Absorption; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chromatog | 1994 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
[Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Administration Sch | 1994 |
[Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Administration Sch | 1994 |
[Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1994 |
[Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1994 |
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
[A study of arterial infusion chemotherapy for gastric cancer patients with peritoneal metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Routes; Fluorouracil; | 1996 |
[A study of arterial infusion chemotherapy for gastric cancer patients with peritoneal metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Routes; Fluorouracil; | 1996 |
[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female | 1996 |
[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female | 1996 |
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Female; Fluorour | 1996 |
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Female; Fluorour | 1996 |
Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1996 |
Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1996 |
[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma 256, Walker; Chemotherapy | 1997 |
[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma 256, Walker; Chemotherapy | 1997 |
[Therapeutic efficacy of intra-peritoneal infusion of cisplatin and continuous intravenous infusion of 5-fluorouracil in gastric cancer patients with peritoneal metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1999 |
[Therapeutic efficacy of intra-peritoneal infusion of cisplatin and continuous intravenous infusion of 5-fluorouracil in gastric cancer patients with peritoneal metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1999 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2000 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2000 |
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic N | 2000 |
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic N | 2000 |
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2001 |
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2001 |
A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2001 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Intraperitoneal administration of recombinant interferon-beta for prevention in peritoneal metastasis of gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Huma | 1990 |
[Intraperitoneal administration of recombinant interferon-beta for prevention in peritoneal metastasis of gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Huma | 1990 |
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer.
Topics: Adult; Aged; Cisplatin; Drug Combinations; Drug Synergism; Feasibility Studies; Female; Fluorouracil | 1990 |
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer.
Topics: Adult; Aged; Cisplatin; Drug Combinations; Drug Synergism; Feasibility Studies; Female; Fluorouracil | 1990 |
338 other studies available for fluorouracil and Peritoneal Neoplasms
| Article | Year |
|---|---|
Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
Topics: Aerosols; Cohort Studies; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Humans; Leucovori | 2022 |
Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
Topics: Aerosols; Cohort Studies; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Humans; Leucovori | 2022 |
[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2022 |
[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2022 |
Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Colonic Neoplasms; Fl | 2023 |
Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Colonic Neoplasms; Fl | 2023 |
Clinical effectiveness of fluorouracil and cisplatin intraperitoneal perfusion combined with intravenous chemotherapy for peritoneal metastasis in gastric cancer.
Topics: Case-Control Studies; Cisplatin; Fluorouracil; Humans; Perfusion; Peritoneal Neoplasms; Quality of L | 2023 |
Clinical effectiveness of fluorouracil and cisplatin intraperitoneal perfusion combined with intravenous chemotherapy for peritoneal metastasis in gastric cancer.
Topics: Case-Control Studies; Cisplatin; Fluorouracil; Humans; Perfusion; Peritoneal Neoplasms; Quality of L | 2023 |
Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: A mouse model study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Models, Anima | 2020 |
Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: A mouse model study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Models, Anima | 2020 |
FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2019 |
FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2019 |
Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.
Topics: Animals; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Mal | 2020 |
Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.
Topics: Animals; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Mal | 2020 |
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neopla | 2019 |
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neopla | 2019 |
Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Fem | 2020 |
Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Fem | 2020 |
shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorou | 2020 |
shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorou | 2020 |
[A Case of Unresectable Sigmoid Colon Cancer with Peritoneal Dissemination Treated with Chemotherapy after an Unintended Emergency Jejunostomy Formation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Fluorouracil; Humans; Jejunostomy; | 2019 |
[A Case of Unresectable Sigmoid Colon Cancer with Peritoneal Dissemination Treated with Chemotherapy after an Unintended Emergency Jejunostomy Formation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Fluorouracil; Humans; Jejunostomy; | 2019 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2020 |
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2020 |
[Transverse Colon Cancer with Peritoneal Metastasis Successfully Treated with mFOLFOX6 plus Bevacizumab-A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colon, Transverse; C | 2020 |
[Transverse Colon Cancer with Peritoneal Metastasis Successfully Treated with mFOLFOX6 plus Bevacizumab-A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colon, Transverse; C | 2020 |
Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu | 2020 |
Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu | 2020 |
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Intravenous; Adolescent; Adult; Aged; Aged | 2020 |
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Intravenous; Adolescent; Adult; Aged; Aged | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross- | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross- | 2020 |
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug | 2021 |
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug | 2021 |
Results from the PROPHYLOCHIP-PRODIGE 15 trial.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Peritoneal Neoplasms; Retrospective Studies | 2020 |
Results from the PROPHYLOCHIP-PRODIGE 15 trial.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Peritoneal Neoplasms; Retrospective Studies | 2020 |
Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Comb | 2020 |
Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Comb | 2020 |
Is it a case series? Comment on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei".
Topics: Fluorouracil; Humans; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2021 |
Is it a case series? Comment on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei".
Topics: Fluorouracil; Humans; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2021 |
Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therap | 2021 |
Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therap | 2021 |
Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model.
Topics: Animals; Antineoplastic Agents; Biological Availability; Colorectal Neoplasms; Combined Modality The | 2021 |
Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model.
Topics: Animals; Antineoplastic Agents; Biological Availability; Colorectal Neoplasms; Combined Modality The | 2021 |
Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Coloring Agents; Co | 2018 |
Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Coloring Agents; Co | 2018 |
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2017 |
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2017 |
Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2017 |
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2017 |
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cecal Neoplasms | 2017 |
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cecal Neoplasms | 2017 |
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec | 2018 |
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec | 2018 |
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; | 2018 |
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; | 2018 |
Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Camptothecin; Carcinoid Tumor | 2019 |
Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Camptothecin; Carcinoid Tumor | 2019 |
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neo | 2019 |
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neo | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; | 2019 |
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2019 |
Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S | 2013 |
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S | 2013 |
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2013 |
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2013 |
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2013 |
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; | 2013 |
[Successful treatment of a patient using mFOLFOX6 after laparoscopic surgery for rectal cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Lap | 2013 |
[Successful treatment of a patient using mFOLFOX6 after laparoscopic surgery for rectal cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Lap | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
[A case wherein bevacizumab/XELOX combination therapy was remarkably effective for the treatment of extensive dissemination in advanced colon cancer, and the primary lesion could be resected].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[A case wherein bevacizumab/XELOX combination therapy was remarkably effective for the treatment of extensive dissemination in advanced colon cancer, and the primary lesion could be resected].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2014 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2014 |
Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells.
Topics: Antineoplastic Agents; Bromelains; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; D | 2014 |
Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells.
Topics: Antineoplastic Agents; Bromelains; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; D | 2014 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Ind | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Ind | 2014 |
[A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Duodena | 2014 |
[A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Duodena | 2014 |
Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2014 |
Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2014 |
Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems | 2014 |
Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems | 2014 |
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA Methylation; | 2014 |
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA Methylation; | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations | 2014 |
Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplas | 2014 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplas | 2014 |
[Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Laparoscopy; Pallia | 2014 |
[Safety and efficacy of intraperitoneal hyperthermic perfusion chemotherapy following laparoscopic palliative resection for gastric cancer patients with peritoneal metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Laparoscopy; Pallia | 2014 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2015 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2015 |
[Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Moda | 2014 |
[Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Moda | 2014 |
Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Ch | 2015 |
Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Ch | 2015 |
[A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2014 |
[A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col | 2014 |
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2015 |
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2015 |
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytoreduction S | 2014 |
Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytoreduction S | 2014 |
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Prolifera | 2015 |
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Prolifera | 2015 |
Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Cytoreduction | 2015 |
Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Cytoreduction | 2015 |
The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Disease Models, | 2016 |
The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Disease Models, | 2016 |
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2017 |
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2017 |
[Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; | 2015 |
[Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; | 2015 |
[A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colectomy; Consciousness; Fem | 2015 |
[A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colectomy; Consciousness; Fem | 2015 |
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Combined M | 2016 |
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Combined M | 2016 |
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2016 |
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2016 |
Pseudomyxoma Peritonei in a Patient with History of Breast Cancer.
Topics: Abdomen; Aged; Antimetabolites, Antineoplastic; Ascites; Breast Neoplasms; Colonoscopy; Female; Fluo | 2016 |
Pseudomyxoma Peritonei in a Patient with History of Breast Cancer.
Topics: Abdomen; Aged; Antimetabolites, Antineoplastic; Ascites; Breast Neoplasms; Colonoscopy; Female; Fluo | 2016 |
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisp | 2016 |
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisp | 2016 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; | 2016 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; | 2016 |
Jackhammer oesophagus in a case of linitis plastica.
Topics: Cisplatin; Colonoscopy; Diagnosis, Differential; Docetaxel; Esophagus; Fatal Outcome; Female; Fluoro | 2016 |
Jackhammer oesophagus in a case of linitis plastica.
Topics: Cisplatin; Colonoscopy; Diagnosis, Differential; Docetaxel; Esophagus; Fatal Outcome; Female; Fluoro | 2016 |
[Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; | 2016 |
[Study of introperitoneal hyperthermic perfusion chemotherapy combined with systemic neoadjuvent chemotherapy in treatment of gastric cancer patients with peritoneal carcinomatosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition | 2016 |
Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients.
Topics: Analgesia, Epidural; Analgesia, Patient-Controlled; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients.
Topics: Analgesia, Epidural; Analgesia, Patient-Controlled; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2017 |
Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2017 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmac | 2017 |
Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmac | 2017 |
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
Topics: Administration, Intravenous; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Chloride | 2017 |
Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
Topics: Administration, Intravenous; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Chloride | 2017 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxy | 2017 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxy | 2017 |
Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer.
Topics: Animals; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Fluorouracil; Gastrec | 2018 |
Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer.
Topics: Animals; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Fluorouracil; Gastrec | 2018 |
"
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal | 2016 |
"
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal | 2016 |
Reduction of carcinomatosis risk using icodextrin as a carrier solution of intraperitoneal oxaliplatin chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cell Movement; | 2017 |
Reduction of carcinomatosis risk using icodextrin as a carrier solution of intraperitoneal oxaliplatin chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cell Movement; | 2017 |
Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2017 |
Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2017 |
[A Case of Mucinous Adenocarcinoma of the Appendix with Peritoneal Dissemination Diagnosed by Laparoscopic Abdominal Exploration and Appendectomy].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal | 2016 |
[A Case of Mucinous Adenocarcinoma of the Appendix with Peritoneal Dissemination Diagnosed by Laparoscopic Abdominal Exploration and Appendectomy].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal | 2016 |
Granulocyte-colony stimulating factor producing rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome; | 2008 |
Granulocyte-colony stimulating factor producing rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome; | 2008 |
Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell | 2008 |
Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell | 2008 |
[Combination chemotherapy composed of mFOLFOX 6, FOLFIRI 2 and surgery and radiation therapy for locoregional recurrences and multiple lung metastases from rectal cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cisplatin; C | 2008 |
[Combination chemotherapy composed of mFOLFOX 6, FOLFIRI 2 and surgery and radiation therapy for locoregional recurrences and multiple lung metastases from rectal cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cisplatin; C | 2008 |
Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Fem | 2008 |
Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Fem | 2008 |
Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female | 2008 |
Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female | 2008 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2008 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2008 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 2008 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 2008 |
[Super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy--report of a case].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic | 2008 |
[Super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy--report of a case].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic | 2008 |
Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4).
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Che | 2008 |
Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4).
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Che | 2008 |
[A case of advanced sigmoid colon cancer with peritoneal dissemination responding to FOLFOX4 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Female; Fluorouracil; Huma | 2008 |
[A case of advanced sigmoid colon cancer with peritoneal dissemination responding to FOLFOX4 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Female; Fluorouracil; Huma | 2008 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Appendectomy; Append | 2009 |
Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Appendectomy; Append | 2009 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; C | 2009 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; C | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; E | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; E | 2009 |
Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
Topics: Adenoma, Villous; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
Topics: Adenoma, Villous; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mice; | 2009 |
Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mice; | 2009 |
[Metastazation into the seminal vesicles due to primary goblet cell carcinoid of the vermiform appendix. An unusual diagnostic procedure of a seminal vesicle tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Appendix; Bioma | 2009 |
[Metastazation into the seminal vesicles due to primary goblet cell carcinoid of the vermiform appendix. An unusual diagnostic procedure of a seminal vesicle tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Appendix; Bioma | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Female; | 2009 |
Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Female; | 2009 |
Gallbladder squamous cell carcinoma in the setting of low-dose methotrexate use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholecystectomy, Lap | 2009 |
Gallbladder squamous cell carcinoma in the setting of low-dose methotrexate use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholecystectomy, Lap | 2009 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2010 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2010 |
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; France; Humans; H | 2010 |
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; France; Humans; H | 2010 |
Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
Topics: Adult; Aged; Antineoplastic Agents; Ascites; Chemotherapy, Cancer, Regional Perfusion; Female; Fluor | 2010 |
Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites.
Topics: Adult; Aged; Antineoplastic Agents; Ascites; Chemotherapy, Cancer, Regional Perfusion; Female; Fluor | 2010 |
Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2010 |
Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2010 |
Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cell Line, Tumor; Chromatography, High Pressu | 2010 |
Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cell Line, Tumor; Chromatography, High Pressu | 2010 |
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluor | 2010 |
5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluor | 2010 |
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
Topics: Adult; Antineoplastic Agents; Cell Differentiation; Cell Transformation, Neoplastic; Disease Progres | 2010 |
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
Topics: Adult; Antineoplastic Agents; Cell Differentiation; Cell Transformation, Neoplastic; Disease Progres | 2010 |
Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Com | 2010 |
Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Com | 2010 |
[A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
[A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; In | 2011 |
Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; In | 2011 |
Pharmacology of perioperative 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Female; Fluorouracil; Humans; I | 2010 |
Pharmacology of perioperative 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Female; Fluorouracil; Humans; I | 2010 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Ch | 2010 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Ch | 2010 |
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antin | 2011 |
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antin | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Di | 2010 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Di | 2010 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2011 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2011 |
Enhanced anti-cancer effect of 5-fluorouracil loaded into thermo-responsive conjugated linoleic acid-incorporated poloxamer hydrogel on metastatic colon cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Drug Deli | 2011 |
Enhanced anti-cancer effect of 5-fluorouracil loaded into thermo-responsive conjugated linoleic acid-incorporated poloxamer hydrogel on metastatic colon cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Drug Deli | 2011 |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Feasibility Studies; Female; F | 2012 |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Feasibility Studies; Female; F | 2012 |
Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doce | 2011 |
Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doce | 2011 |
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2011 |
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2011 |
Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic | 2012 |
Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic | 2012 |
Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood | 2012 |
Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood | 2012 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.
Topics: Animals; Ascites; Fluorouracil; Injections, Intravenous; Kaplan-Meier Estimate; Liposomes; Male; Mic | 2011 |
Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.
Topics: Animals; Ascites; Fluorouracil; Injections, Intravenous; Kaplan-Meier Estimate; Liposomes; Male; Mic | 2011 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo | 2011 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo | 2011 |
[mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2011 |
[mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2011 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; | 2012 |
Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; | 2012 |
Metastatic paediatric colorectal carcinoma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2012 |
Metastatic paediatric colorectal carcinoma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2012 |
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2012 |
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2012 |
[A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fatal Outcome; Female; Fluorourac | 2012 |
[A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fatal Outcome; Female; Fluorourac | 2012 |
[A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Co | 2012 |
[A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Co | 2012 |
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
[A case of small intestinal cancer with peritoneal metastases treated with FOLFOX regimen].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Jejunal Neoplasms; Leuc | 2012 |
[A case of small intestinal cancer with peritoneal metastases treated with FOLFOX regimen].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Jejunal Neoplasms; Leuc | 2012 |
Posterior reversible encephalopathy syndrome (PRES) after treatment with oxaliplatin and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Female; Fluorouracil; Humans; | 2013 |
Posterior reversible encephalopathy syndrome (PRES) after treatment with oxaliplatin and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Female; Fluorouracil; Humans; | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.
Topics: Activities of Daily Living; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineopla | 2012 |
Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.
Topics: Activities of Daily Living; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineopla | 2012 |
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 2012 |
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 2012 |
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
A novel nomogram for peritoneal mesothelioma predicts survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Ba | 2013 |
A novel nomogram for peritoneal mesothelioma predicts survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Ba | 2013 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
[A long-term survivor of colorectal cancer associated with multiple liver metastases and peritoneal carcinomatosis treated through a multidisciplinary approach].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Human | 2012 |
[A long-term survivor of colorectal cancer associated with multiple liver metastases and peritoneal carcinomatosis treated through a multidisciplinary approach].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Human | 2012 |
[A case report of successful treatment for rectosigmoid cancer with peritoneal dissemination after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[A case report of successful treatment for rectosigmoid cancer with peritoneal dissemination after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonic Neoplasms; D | 2013 |
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonic Neoplasms; D | 2013 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati | 2002 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati | 2002 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2002 |
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2002 |
[Combination chemotherapy with intra-perioneal infusion of CDDP and continuous intravenous infusion of 5-FU for peritoneal metastasis in gastric cancer--analysis of long-term survivors].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Therapy, Combin | 2002 |
[Combination chemotherapy with intra-perioneal infusion of CDDP and continuous intravenous infusion of 5-FU for peritoneal metastasis in gastric cancer--analysis of long-term survivors].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Therapy, Combin | 2002 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
A case of aggressive neuroendocrine carcinoma of the stomach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
A case of aggressive neuroendocrine carcinoma of the stomach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2003 |
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
[FRICTION RUB SOUNDS IN THE ABDOMEN].
Topics: Abdomen; Auscultation; Blood Protein Electrophoresis; Cyclophosphamide; Fluorouracil; Friction; Geri | 1964 |
[FRICTION RUB SOUNDS IN THE ABDOMEN].
Topics: Abdomen; Auscultation; Blood Protein Electrophoresis; Cyclophosphamide; Fluorouracil; Friction; Geri | 1964 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Autoradiography; Colonic Neoplasms; Female | 2004 |
Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Autoradiography; Colonic Neoplasms; Female | 2004 |
Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; M | 2004 |
Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; M | 2004 |
[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2004 |
[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2004 |
Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Fluorouracil; Hemostatics; Infusions, Intraveno | 2004 |
Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Fluorouracil; Hemostatics; Infusions, Intraveno | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
[A case of advanced descending colon cancer with peritoneal dissemination responding to weekly high-dose l-leucovorin/5-fluorouracil combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respon | 2004 |
[A case of advanced descending colon cancer with peritoneal dissemination responding to weekly high-dose l-leucovorin/5-fluorouracil combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respon | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2004 |
[Extensive peritonectomy. A new treatment approach to pseudomyxoma peritonei].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2004 |
[Extensive peritonectomy. A new treatment approach to pseudomyxoma peritonei].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase | 2004 |
Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2005 |
Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2005 |
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
[A case of the 5-year survivor of ascending colon cancer associated with synchronous multiple liver metastasis and peritoneal dissemination successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colonic Neoplasms; Embolization, Therapeutic | 2004 |
[A case of the 5-year survivor of ascending colon cancer associated with synchronous multiple liver metastasis and peritoneal dissemination successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colonic Neoplasms; Embolization, Therapeutic | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic | 2004 |
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color | 2004 |
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color | 2004 |
A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Cisplatin; Diagnosis, Differential; Female; | 2005 |
A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Cisplatin; Diagnosis, Differential; Female; | 2005 |
[A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biliary Tract; Chemotherapy, Adjuvant; Drug | 2005 |
[A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biliary Tract; Chemotherapy, Adjuvant; Drug | 2005 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Topics: Animals; Antibodies, Viral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality | 2005 |
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Topics: Animals; Antibodies, Viral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality | 2005 |
Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combine | 2005 |
Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combine | 2005 |
[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemot | 2005 |
[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemot | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2005 |
Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2005 |
Regional delivery of model compounds and 5-Fluorouracil to the liver by their application to the liver surface in rats: its implication for clinical use.
Topics: Absorption; Animals; Antineoplastic Agents; Area Under Curve; Drug Delivery Systems; Fluorescein-5-i | 2005 |
Regional delivery of model compounds and 5-Fluorouracil to the liver by their application to the liver surface in rats: its implication for clinical use.
Topics: Absorption; Animals; Antineoplastic Agents; Area Under Curve; Drug Delivery Systems; Fluorescein-5-i | 2005 |
Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fertility; Fluorouracil; H | 2006 |
Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fertility; Fluorouracil; H | 2006 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Flu | 2005 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Flu | 2005 |
Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Injections, Intravenous; Kidney Failure, Chro | 2005 |
Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Injections, Intravenous; Kidney Failure, Chro | 2005 |
Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Par | 2005 |
Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Par | 2005 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; | 2005 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; | 2005 |
[Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Drug Therapy, | 2005 |
[Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Drug Therapy, | 2005 |
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2006 |
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2006 |
Oxaliplatin-related acute myelogenous leukemia.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
Oxaliplatin-related acute myelogenous leukemia.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma | 2006 |
Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma | 2006 |
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxe | 2006 |
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxe | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fl | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fl | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administra | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administra | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2006 |
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2006 |
[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2006 |
[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; | 2007 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; | 2007 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothera | 2007 |
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothera | 2007 |
[Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chemotherapy, Adjuvant; Cisplati | 2006 |
[Complete regression after neoadjuvant chemotherapy in locally advanced gastric cancer causing peritonitis carcinomatosa--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chemotherapy, Adjuvant; Cisplati | 2006 |
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Female; Fluoro | 2007 |
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Female; Fluoro | 2007 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Appen | 2007 |
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Appen | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul | 2007 |
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Topics: Camptothecin; Cisplatin; Cytotoxins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; H | 2008 |
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Topics: Camptothecin; Cisplatin; Cytotoxins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; H | 2008 |
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2007 |
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2007 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, | 2007 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, | 2007 |
[A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoembryonic Antigen; Combined M | 2007 |
[A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoembryonic Antigen; Combined M | 2007 |
Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2008 |
Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2008 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; | 2009 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; | 2009 |
Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2008 |
Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
[Long-term maintenance chemotherapy for pseudomyxoma peritonei of ovarian origin].
Topics: Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; Neoplasm Seeding; O | 1984 |
[Long-term maintenance chemotherapy for pseudomyxoma peritonei of ovarian origin].
Topics: Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; Neoplasm Seeding; O | 1984 |
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle | 1984 |
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
[Malignant mesothelioma of the peritoneum. Case report].
Topics: Adult; Antineoplastic Agents; Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Fem | 1983 |
[Malignant mesothelioma of the peritoneum. Case report].
Topics: Adult; Antineoplastic Agents; Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Fem | 1983 |
Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Intra-Arterial; | 1982 |
Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Intra-Arterial; | 1982 |
An experimental model for treatment of mesothelioma.
Topics: Animals; Asbestos; Body Weight; Cricetinae; Cyclophosphamide; Disease Models, Animal; Doxorubicin; F | 1981 |
An experimental model for treatment of mesothelioma.
Topics: Animals; Asbestos; Body Weight; Cricetinae; Cyclophosphamide; Disease Models, Animal; Doxorubicin; F | 1981 |
The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Kinetics; Methotrexate; Peritoneal Dialysis; Peritoneal | 1980 |
The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Kinetics; Methotrexate; Peritoneal Dialysis; Peritoneal | 1980 |
[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 1995 |
[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 1995 |
Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Fluor | 1994 |
Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Fluor | 1994 |
Treatment of pseudomyxoma peritonei in a geriatric patient population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
Treatment of pseudomyxoma peritonei in a geriatric patient population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 1995 |
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 1995 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden | 1994 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden | 1994 |
Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1994 |
Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1994 |
[Dual arterial infusion chemotherapy, continuous hyperthermic peritoneal perfusion, and total parietal peritonectomy for peritoneal dissemination in gastric cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality The | 1994 |
[Dual arterial infusion chemotherapy, continuous hyperthermic peritoneal perfusion, and total parietal peritonectomy for peritoneal dissemination in gastric cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality The | 1994 |
[Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cel | 1994 |
[Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cel | 1994 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Moda | 1993 |
In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Moda | 1993 |
Bioavailability of subcutaneous 5-fluorouracil: a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma; Colorectal Neoplasms | 1996 |
Bioavailability of subcutaneous 5-fluorouracil: a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma; Colorectal Neoplasms | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colonic Neoplasms; Female; Fluorouracil; | 1996 |
Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colonic Neoplasms; Female; Fluorouracil; | 1996 |
[Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 1996 |
[Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 1996 |
CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer.
Topics: Adult; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Female; Fluorouracil; Hu | 1996 |
CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer.
Topics: Adult; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Female; Fluorouracil; Hu | 1996 |
Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Drug Screening Assays, Antitumor; Fluorouracil; | 1996 |
Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Drug Screening Assays, Antitumor; Fluorouracil; | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
New principles, better practices, and clearer perceptions in intraperitoneal chemotherapy: clinical experience using icodextrin 20 as a carrier solution.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dialysis Solutions; Drug Carriers; Fluorouracil; Gl | 1997 |
New principles, better practices, and clearer perceptions in intraperitoneal chemotherapy: clinical experience using icodextrin 20 as a carrier solution.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dialysis Solutions; Drug Carriers; Fluorouracil; Gl | 1997 |
[Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1997 |
[Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1997 |
[Effect of preoperative THP-FLPM (pirarubicin, 5-fluorouracil, leucovorin, cisplatin, mitomycin C) therapy on far advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 1998 |
[Effect of preoperative THP-FLPM (pirarubicin, 5-fluorouracil, leucovorin, cisplatin, mitomycin C) therapy on far advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 1998 |
Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice.
Topics: Animals; Biocompatible Materials; Colonic Neoplasms; Fluorouracil; Injections, Intraperitoneal; Lact | 1998 |
Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice.
Topics: Animals; Biocompatible Materials; Colonic Neoplasms; Fluorouracil; Injections, Intraperitoneal; Lact | 1998 |
[Pharmaco-dynamic influence under ascites or laparotomy on intraperitoneal sequential MTX/5-FU therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Fluorouracil; Gastrectomy; Humans; In | 1998 |
[Pharmaco-dynamic influence under ascites or laparotomy on intraperitoneal sequential MTX/5-FU therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Fluorouracil; Gastrectomy; Humans; In | 1998 |
[Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1998 |
[Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1998 |
[Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 1998 |
[Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 1998 |
[Perspectives in the treatment of peritoneal carcinosis].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
[Perspectives in the treatment of peritoneal carcinosis].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1998 |
Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1998 |
Pseudomyxoma peritonei: Sudden cardiac death complicating post operative intraperitoneal treatment with 5-fluorouracil.
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Death, Sudden, Cardiac; Fluorouracil | 1999 |
Pseudomyxoma peritonei: Sudden cardiac death complicating post operative intraperitoneal treatment with 5-fluorouracil.
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Death, Sudden, Cardiac; Fluorouracil | 1999 |
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic | 1999 |
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic | 1999 |
[A case of type 4 gastric cancer with peritoneal dissemination treated with intra-aortic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 1999 |
[A case of type 4 gastric cancer with peritoneal dissemination treated with intra-aortic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 1999 |
Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Ad | 1999 |
Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Ad | 1999 |
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
[Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Cisplati | 1999 |
[Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Cisplati | 1999 |
Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Interferon-alpha; Jejun | 2000 |
Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Interferon-alpha; Jejun | 2000 |
[A case of unresectable gallbladder cancer responding to combination therapy with hyperthermia and local chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2000 |
[A case of unresectable gallbladder cancer responding to combination therapy with hyperthermia and local chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2000 |
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin | 2000 |
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin | 2000 |
[A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2000 |
[A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2000 |
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Region | 2000 |
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Region | 2000 |
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2001 |
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2001 |
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 2001 |
Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 2001 |
Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Digestive Syste | 2001 |
Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Digestive Syste | 2001 |
Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Diagn | 2001 |
Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Diagn | 2001 |
Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
Topics: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2001 |
Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
Topics: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2001 |
[A case of intra-peritoneal recurrence of colon carcinoma that responded remarkably to combined therapy of low-dose leucovorin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2001 |
[A case of intra-peritoneal recurrence of colon carcinoma that responded remarkably to combined therapy of low-dose leucovorin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2001 |
Prophylaxis of peritoneal carcinomatosis in experimental investigations.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Fluorouracil; Infusions, Parenteral; Male | 2001 |
Prophylaxis of peritoneal carcinomatosis in experimental investigations.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Fluorouracil; Infusions, Parenteral; Male | 2001 |
[Efficacy of intraperitoneal chemotherapy for peritoneal recurrence of gastric carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2001 |
[Efficacy of intraperitoneal chemotherapy for peritoneal recurrence of gastric carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2001 |
Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2001 |
Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2001 |
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Fluorourac | 2001 |
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Fluorourac | 2001 |
Cytoreduction including total gastrectomy for pseudomyxoma peritonei.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile; Blood Loss, Surgical; Combined Modality Therapy; | 2002 |
Cytoreduction including total gastrectomy for pseudomyxoma peritonei.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile; Blood Loss, Surgical; Combined Modality Therapy; | 2002 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System S | 2002 |
Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System S | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.
Topics: Adult; Antineoplastic Agents; Ascitic Fluid; Contrast Media; Female; Fluorouracil; Humans; Injection | 1979 |
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.
Topics: Adult; Antineoplastic Agents; Ascitic Fluid; Contrast Media; Female; Fluorouracil; Humans; Injection | 1979 |
Pancreatitis during combination chemotherapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Me | 1979 |
Pancreatitis during combination chemotherapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Me | 1979 |
[Chemotherapy of intestinal carcinomas].
Topics: Cyclophosphamide; Fluorouracil; Humans; Intestinal Neoplasms; Peritoneal Neoplasms | 1979 |
[Chemotherapy of intestinal carcinomas].
Topics: Cyclophosphamide; Fluorouracil; Humans; Intestinal Neoplasms; Peritoneal Neoplasms | 1979 |
[Experience with chemotherapy in peritoneal carcinosis].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1977 |
[Experience with chemotherapy in peritoneal carcinosis].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1977 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Chemotherapy of malignant diffuse mesothelioma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; | 1976 |
Chemotherapy of malignant diffuse mesothelioma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; | 1976 |
[Pancreatic endocrine tumor with metastases and increase of alpha-fetoprotein. A case report].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fatal Outcome; Fluoroura | 1992 |
[Pancreatic endocrine tumor with metastases and increase of alpha-fetoprotein. A case report].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fatal Outcome; Fluoroura | 1992 |
Prevention of 5-fluorouracil-induced infection with indigenous Escherichia coli in tumor-bearing mice by nonspecific immunostimulation.
Topics: Animals; Bacterial Vaccines; Escherichia coli Infections; Fibrosarcoma; Fluorouracil; Lacticaseibaci | 1992 |
Prevention of 5-fluorouracil-induced infection with indigenous Escherichia coli in tumor-bearing mice by nonspecific immunostimulation.
Topics: Animals; Bacterial Vaccines; Escherichia coli Infections; Fibrosarcoma; Fluorouracil; Lacticaseibaci | 1992 |
[Effective treatment of liver metastasis and peritoneal dissemination of gastric cancer using intra-arterial therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administration Schedule; Fluoro | 1992 |
[Effective treatment of liver metastasis and peritoneal dissemination of gastric cancer using intra-arterial therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administration Schedule; Fluoro | 1992 |
[Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Screening Assays, Antitumor; Female; | 1992 |
[Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Screening Assays, Antitumor; Female; | 1992 |
[Studies on a slow releasing anticancer agent for prevention of peritoneal recurrence of advanced gastrointestinal carcinomas (clinical study)].
Topics: Delayed-Action Preparations; Duodenal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Lactat | 1992 |
[Studies on a slow releasing anticancer agent for prevention of peritoneal recurrence of advanced gastrointestinal carcinomas (clinical study)].
Topics: Delayed-Action Preparations; Duodenal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Lactat | 1992 |
[Studies on a slow releasing anticancer agent for prevention of peritoneal recurrence of advanced gastrointestinal carcinomas (experimental study)].
Topics: Animals; Delayed-Action Preparations; Fluorouracil; Infusions, Parenteral; Liver Neoplasms, Experime | 1991 |
[Studies on a slow releasing anticancer agent for prevention of peritoneal recurrence of advanced gastrointestinal carcinomas (experimental study)].
Topics: Animals; Delayed-Action Preparations; Fluorouracil; Infusions, Parenteral; Liver Neoplasms, Experime | 1991 |
Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoid Tumor; | 1991 |
Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoid Tumor; | 1991 |
[Superior mesenteric arterial infusion chemotherapy against intestinal obstruction caused by peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1991 |
[Superior mesenteric arterial infusion chemotherapy against intestinal obstruction caused by peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colonic Neoplasm | 1990 |
Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colonic Neoplasm | 1990 |
[Evaluation of the liver and peritoneal metastasis in the treatment of gastric carcinoma with intra-arterial injection in terms of survival period].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Int | 1990 |
[Evaluation of the liver and peritoneal metastasis in the treatment of gastric carcinoma with intra-arterial injection in terms of survival period].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Int | 1990 |
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
Topics: Chromatography, High Pressure Liquid; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neop | 1990 |
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
Topics: Chromatography, High Pressure Liquid; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neop | 1990 |
[An unresectable colon cancer with a diffuse metastases that turned resectable following thermotherapy with chemoimmunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1990 |
[An unresectable colon cancer with a diffuse metastases that turned resectable following thermotherapy with chemoimmunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1990 |
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; | 1990 |
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; | 1990 |
[A case of nonresectable gastric cancer completely responding to combined chemotherapy according to the mode of progression].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
[A case of nonresectable gastric cancer completely responding to combined chemotherapy according to the mode of progression].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases.
Topics: Animals; Catheterization; Colonic Neoplasms; Fluorouracil; Liver Neoplasms; Male; Neoplasm Transplan | 1990 |
Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases.
Topics: Animals; Catheterization; Colonic Neoplasms; Fluorouracil; Liver Neoplasms; Male; Neoplasm Transplan | 1990 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Intracavitary 5-fluoro-uracil (5-FU) in combination with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Combined Modalit | 1989 |
Intracavitary 5-fluoro-uracil (5-FU) in combination with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Combined Modalit | 1989 |
Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1989 |
Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1989 |
[Experimental study of anti-tumor agent microcapsules--the effects of embolization and drug releasing].
Topics: Animals; Capsules; Dogs; Embolization, Therapeutic; Fluorouracil; Humans; Iodized Oil; Mice; Periton | 1988 |
[Experimental study of anti-tumor agent microcapsules--the effects of embolization and drug releasing].
Topics: Animals; Capsules; Dogs; Embolization, Therapeutic; Fluorouracil; Humans; Iodized Oil; Mice; Periton | 1988 |
Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Topics: Animals; Bone Marrow; Colonic Neoplasms; Diphosphates; Female; Fluorouracil; Kinetics; Mice; Mice, I | 1985 |
Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Topics: Animals; Bone Marrow; Colonic Neoplasms; Diphosphates; Female; Fluorouracil; Kinetics; Mice; Mice, I | 1985 |
[Cytostatic treatment of pseudomyxoma peritonei].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; F | 1985 |
[Cytostatic treatment of pseudomyxoma peritonei].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; F | 1985 |
Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cy | 1987 |
Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cy | 1987 |
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
Topics: Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; | 1988 |
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
Topics: Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; | 1988 |
Development of carcinoma in regional enteritis.
Topics: Adenocarcinoma, Mucinous; Barium Sulfate; Cecum; Colon; Colonic Diseases; Crohn Disease; Enema; Fluo | 1974 |
Development of carcinoma in regional enteritis.
Topics: Adenocarcinoma, Mucinous; Barium Sulfate; Cecum; Colon; Colonic Diseases; Crohn Disease; Enema; Fluo | 1974 |
Pseudomyxoma peritonaei: a report of ten cases.
Topics: Adenocarcinoma; Adult; Aged; Appendectomy; Appendiceal Neoplasms; Castration; Cystadenoma; Female; F | 1973 |
Pseudomyxoma peritonaei: a report of ten cases.
Topics: Adenocarcinoma; Adult; Aged; Appendectomy; Appendiceal Neoplasms; Castration; Cystadenoma; Female; F | 1973 |
Chemotherapy of malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Glucosamine; Humans; Male; Mesothelioma; M | 1974 |
Chemotherapy of malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Glucosamine; Humans; Male; Mesothelioma; M | 1974 |
Disappearance of disseminated pancreatic carcinoma with combined chemotherapy.
Topics: Adult; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Duodenum; Fluorouracil; Gastrectomy; Hum | 1973 |
Disappearance of disseminated pancreatic carcinoma with combined chemotherapy.
Topics: Adult; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Duodenum; Fluorouracil; Gastrectomy; Hum | 1973 |
Observations with a variant of lymphocytic choriomeningitis virus in mouse tumors.
Topics: Animals; Antigens; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Immunotherapy; Lymphocytic Chorio | 1970 |
Observations with a variant of lymphocytic choriomeningitis virus in mouse tumors.
Topics: Animals; Antigens; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Immunotherapy; Lymphocytic Chorio | 1970 |
[Continuous intra-arterial infusion of antineoplastic agents in cancerous peritonitis, with special reference to cancer].
Topics: Adult; Aged; Cytarabine; Female; Femoral Artery; Fluorouracil; Humans; Injections, Intra-Arterial; M | 1971 |
[Continuous intra-arterial infusion of antineoplastic agents in cancerous peritonitis, with special reference to cancer].
Topics: Adult; Aged; Cytarabine; Female; Femoral Artery; Fluorouracil; Humans; Injections, Intra-Arterial; M | 1971 |
Pseudomyxoma peritonei and the appendix.
Topics: Adult; Appendiceal Neoplasms; Cystadenoma; Fluorouracil; Humans; Male; Mucocele; Omentum; Peritoneal | 1970 |
Pseudomyxoma peritonei and the appendix.
Topics: Adult; Appendiceal Neoplasms; Cystadenoma; Fluorouracil; Humans; Male; Mucocele; Omentum; Peritoneal | 1970 |